ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

NexoBrid 2 g powder and gel for gel

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One vial contains 2 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 2 g/22 g gel).

The proteolytic enzymes are a mixture of enzymes from the stem of Ananas comosus (pineapple plant). For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder and gel for gel
The powder is off-white to light tan. The gel is clear and colourless.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

4.2 Posology and method of administration

This medicinal product should only be applied by trained healthcare professionals in specialist burn centres.

Posology

2 g powder in 20 g gel is applied to a burn wound area of 1 % Total Body Surface Area (TBSA) of an adult, with a gel layer thickness of 1.5 to 3 mm.

The gel should not be applied to more than 15% TBSA (see also section 4.4, Coagulopathy).

It should be left in contact with the burn for a duration of 4 hours. There is very limited information on the use of this medicinal product on areas where eschar remained after the first application. A second and subsequent application is not recommended.

Special populations

Renal impairment
There is no information on the use in patients with renal impairment. These patients should be carefully monitored.

Hepatic impairment
There is no information on the use in patients with hepatic impairment. These patients should be carefully monitored.
**Elderly patients**
Experience in elderly patients (>65 years) is limited. No dose adjustment is required.

**Paediatric population**
The safety and efficacy of this treatment in children and adolescents younger than 18 years have not yet been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.
This medicinal product is not indicated for use in patients younger than 18 years.

**Method of administration**

**Cutaneous use.**
Before use, the powder must be mixed with the gel producing a uniform gel. For instructions on mixing see section 6.6.

Once mixed, the gel should be applied to a clean, keratin-free (blisters removed), and moist wound area.

Each vial, gel, or reconstituted gel should be used for a single use only.

Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to application of the gel as eschar saturated with medicinal products and their remains reduce its activity and decrease its efficacy.

For instructions on preparation of the medicinal product before application, see section 6.6.

**Precaution to be taken before manipulating or administering the product**
When mixing this medicinal product powder with the gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and a surgical mask, is required (see section 4.4). The powder should not be inhaled, see section 6.6.

**Preparation of patient and wound area**
A total wound area of not more than 15% TBSA can be treated with this medicinal product (see also section 4.4, Coagulopathy).

- Enzymatic debridement is a painful procedure and requires adequate analgesia and/or anaesthesia. Pain management must be used as commonly practiced for an extensive dressing change; it should be initiated at least 15 minutes prior to NexoBrid application.
- The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with the gel and prevent eschar removal by it.
- Dressing soaked with an antibacterial solution must be applied for 2 hours.
- All topically applied antibacterial medicinal products must be removed before applying the gel. Remaining antibacterial medicinal products may reduce the activity of NexoBrid by decreasing its efficacy.
- The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser). The paraffin layer must not come into contact with the area to be treated to avoid covering the eschar, thus isolating the eschar from direct contact with the gel.
  To prevent possible irritation of abraded skin by inadvertent contact with the gel and possible bleeding from the wound bed, acute wound areas such as lacerations or escharotomy incisions should be protected by a layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).
- Sterile isotonic sodium chloride 9 mg/ml (0.9%) solution must be sprinkled on the burn wound. The wound must be kept moist during the application procedure.

**Application of the gel**
Moisten the area to be treated by sprinkling sterile saline onto the area bordered by the fatty ointment adhesive barrier.

Within 15 minutes of mixing, the gel must be applied topically to the moistened burn wound, at a thickness of 1.5 to 3 millimetres.

The wound must then be covered with a sterile occlusive film dressing that adheres to the sterile adhesive barrier material applied as per the instruction above (see Preparation of patient and wound area). The gel must fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing. Gentle pressing of the occlusive dressing at the area of contact with the adhesive barrier will ensure adherence between the occlusive film and the sterile adhesive barrier and achieve complete containment of the gel on the treatment area.

The dressed wound must be covered with a loose, thick fluffy dressing, held in place with a bandage.

The dressing must remain in place for 4 hours.

Removal of the gel

Removal of this medicinal product is a painful procedure and requires adequate analgesia and/or anaesthesia. Appropriate preventive analgesia medicinal products must be administered at least 15 minutes prior to gel application.

After 4 hours of medicinal product treatment, the occlusive dressing must be removed using aseptic techniques.

The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).

The dissolved eschar must be removed from the wound by wiping it away with a sterile blunt-edged instrument.

The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution. The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue. Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.

A dressing soaked with an antibacterial solution must be applied for an additional 2 hours.

Wound care after debridement

The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.

Before a permanent skin cover or temporary skin substitute is applied to a freshly enzymatically debrided area, a soaking wet-to-dry dressing must be applied.

Before application of the grafts or primary dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or scraping to allow dressing adherence.

Wounds with areas of full-thickness and deep burn should be autografted as soon as possible after the treatment debridement. Careful consideration should also be given to placing permanent skin covers (e.g., autografts) on deep partial thickness wounds soon after the treatment debridement (see section 4.4).

4.3 Contraindications

Hypersensitivity to the active substance, to pineapples, or papain (see also section 4.4), or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions
The potential of this medicinal product (a protein product) to cause sensitisation should be taken into account.

There have been reports of serious allergic reactions including anaphylaxis (with manifestations such as rash, erythema, hypotension, tachycardia) in patients undergoing debridement with the treatment (see section 4.8). In these cases, a causal relationship to this medicinal product was considered possible, but possible allergy to concomitant medicinal products such as opioid analgesics should also be considered. Allergic reactions to inhaled bromelain have been reported in the literature (including anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angiooedema, urticaria, and mucosal and gastrointestinal reactions). No occupational hazard was found in a study assessing the amount of airborne particles during NexoBrid Gel preparation. In addition, a delayed-type allergic skin reaction (cheilitis) after longer-term dermal exposure (mouthwash) as well as suspected sensitisation following oral exposure and following repeated occupational airway exposure have been reported.

History of allergy needs to be established prior to the administration (see sections 4.3 and 6.6).

Skin exposure

In case of skin exposure, this medicinal product should be rinsed off with water to reduce the likelihood of skin sensitisation (see section 6.6).

Cross-sensitivity

Cross-sensitivity between bromelain and papain as well as latex proteins (known as latex-fruit syndrome), bee venom, and olive tree pollen has been reported in the literature.

Analgesia

Enzymatic debridement is a painful procedure, and may only be administered after adequate analgesia and/or anesthesia has been established.

Burn wounds for which this medicinal product is not recommended

This treatment is not recommended for use on:
- penetrating burn wounds where foreign materials (e.g. implants, pacemakers, and shunts) and/or vital structures (e.g. larger vessels, eyes) are or could become exposed during debridement.
- chemical burn wounds.
- wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.
- foot burns in diabetic patients and patients with occlusive vascular disease.
- in electrical burns.

Burns for which there is limited or no experience

There is no experience of the use of medicinal product on perineal and genital burns.

Use in patients with cardiopulmonary and pulmonary disease

This medicinal product should be used with caution in patients with cardiopulmonary and pulmonary disease, including pulmonary burn trauma and suspected pulmonary burn trauma.

Facial burn wounds

There are literature reports of successful use of this medicinal product on facial burn wounds. Burn surgeons without experience in using this medicinal product should not start using it on facial burn wounds. The treatment must be used with caution in such patients.

Eye protection
Direct contact with the eyes must be avoided. Eyes must be carefully protected during treatment of facial burns using fatty ophthalmic ointment on the eyes and adhesive barrier petroleum ointment around to insulate and cover the eyes with occlusive film.

In case of eye exposure, irrigate exposed eyes with copious amounts of water for at least 15 minutes. An ophthalmological exam is recommended prior to and after debridement.

**Systemic absorption**

Concentrate of proteolytic enzymes enriched in bromelain is systemically absorbed from burn wound areas (see section 5.2). There is limited pharmacokinetic data in patients with TBSA of more than 15%. Due to safety considerations (see also section 4.4, Coagulopathy) this medicinal product should not be applied to more than 15% Total Body Surface Area (TBSA).

**Prevention of wound complications**

General principles of proper burn wound care must be adhered to when using this medicinal product. This includes proper wound cover for the exposed tissue (see section 4.2).

In clinical studies, wounds with visible dermal remnants were allowed to heal by spontaneous epithelialisation. In several cases, adequate healing did not occur, and autografting was required at a later date, leading to delays in wound closure which may be associated with increased risk of wound-related complications. Therefore, wounds with areas of full-thickness and deep burn that will not heal spontaneously by epithelialisation in timely manner should be autografted as soon as possible after NexoBrid debridement (see section 5.1). Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement (see sections 4.2 and 4.8).

As in the case of surgically debrided bed, in order to prevent desiccation and/or formation of pseudoeschar and/or infection, the debrided area should be covered immediately by temporary or permanent skin substitutes or dressings. When applying a permanent skin cover (e.g. autograft) or temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided area, care should be taken to clean and refresh the debrided bed by, e.g., brushing or scraping to allow dressing adherence.

**Coagulopathy**

A reduction of platelet aggregation and plasma fibrinogen levels and a moderate increase in partial thromboplastin and prothrombin times have been reported in the literature as possible effects following oral administration of bromelain. *In vitro* and animal data suggest that bromelain can also promote fibrinolysis. During the clinical development of this medicinal product, there was no indication of an increased bleeding tendency or bleeding at the site of debridement.

The treatment should not be used in patients with uncontrolled disorders of coagulation. It should be used with caution in patients under anticoagulant therapy or other medicinal products affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes, e.g. peptic ulcers and sepsis. Patients should be monitored for possible signs of coagulation abnormalities and signs of bleeding.

**Clinical monitoring**

In addition to routine monitoring for burn patients (e.g., vital signs, volume/water/electrolyte status, complete blood count, serum albumin and hepatic enzyme levels), patients treated with this medicinal product should be monitored for:

- Rise in body temperature.
- Signs of local and systemic inflammatory and infectious processes.
- Conditions that could be precipitated or worsened by analgesic premedication (e.g., gastric dilatation, nausea and risk of sudden vomiting, constipation) or antibiotic prophylaxis (e.g., diarrhoea).
- Signs of local or systemic allergic reactions.
Potential effects on haemostasis (see above).

Removal of topically applied antibacterial medicinal products before NexoBrid application

All topically applied antibacterial medicinal products must be removed before applying this medicinal product. Remaining antibacterial medicinal products reduce the activity of this medicinal product by decreasing its efficacy.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Medicinal products that affect coagulation

Reduction of platelet aggregation and plasma fibrinogen levels and a moderate increase in partial thromboplastin and prothrombin times have been reported as possible effects following oral administration of bromelain. *In vitro* and animal data suggest that bromelain can also promote fibrinolysis. Caution and monitoring is therefore needed when prescribing concomitant medicinal products that affect coagulation (see also section 4.4.).

CYP2C8 and CYP 2C9 substrates

The medicinal product, when absorbed, is an inhibitor of cytochrome P450 2C8 (CYP2C8) and P450 2C9 (CYP2C9). This should be taken into account if this medicinal product is used in patients receiving CYP2C8 substrates (including amiodarone, amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone, repaglinide, rosiglitazone, sorafenib and torasemide) and CYP2C9 substrates (including ibuprofen, tolbutamide, glipizide, losartan, celecoxib, warfarin, and phenytoin).

Topical antibacterial medicinal products

Topically applied antibacterial medicinal products (e.g. silver sulfadiazine or povidone iodine) may decrease the efficacy of this medicinal product (see section 4.4).

Fluorouracil and vincristine

Bromelain may enhance the actions of fluorouracil and vincristine. Patients should be monitored for increased toxicity.

ACE inhibitors

Bromelain may enhance the hypotensive effect of ACE inhibitors, causing larger decreases in blood pressure than expected. Blood pressure should be monitored in patients receiving ACE inhibitors.

Benzodiazepines, barbiturates, narcotics and antidepressants

Bromelain may increase drowsiness caused by some medicinal products (e.g., benzodiazepines, barbiturates, narcotics and antidepressants). This should be taken into account when dosing such products.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of concentrate of proteolytic enzymes enriched in bromelain in pregnant women. Animal studies are insufficient to properly assess the potential of this medicinal product to interfere with embryonal/foetal development (see section 5.3).
Since the safe use of medicinal product during pregnancy has not yet been established, it is not recommended during pregnancy.

Breastfeeding

It is unknown whether concentrate of proteolytic enzymes enriched in bromelain or its metabolites are excreted in human milk. A risk to new-borns/infants cannot be excluded. Breast-feeding should be discontinued at least 4 days from NexoBrid application initiation.

Fertility

No studies were performed to assess the effects of this medicinal product on fertility.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions are transient pyrexia/hyperthermia and local pain (incidence of 15.2 % and 4.0% respectively).

Tabulated list of adverse reactions

The following definitions apply to the frequency terminology used hereafter:
very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

The frequencies of the adverse reactions presented below reflect the use of this medicinal product to remove eschar from deep partial- or full-thickness burns in a regimen with local antibacterial prophylaxis, recommended analgesia, as well as coverage of the wound area after application of the treatment for 4 hours with an occlusive dressing for containment of NexoBrid on the wound.

Infections and infestations
Common: Wound infection*

Immune system disorders
Common: Non serious allergic reactions such as rash*
Not known: Serious allergic reactions including anaphylaxis *

Cardiac disorders
Common: Tachycardia*

Skin and subcutaneous tissue disorders
Common: Wound complication*

General disorders and administration site conditions
Very common: Pyrexia/hypertermia*
Common: Local pain*

*see Description of selected adverse reactions below.
* see section 4.4.

Description of selected adverse reactions
**Pyrexia/hyperthermia**

In pooled studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 with routine antibacterial soaking of the treatment area before and after this medicinal product application (see section 4.2), pyrexia or hyperthermia was reported in 15.2% of patients treated with it and in 11.3% of the control patients treated according to standard of care (SOC).

In early studies without antibacterial soaking (Studies MW2001-10-03 and MW2002-04-01), pyrexia or hyperthermia was reported in 35.1% of NexoBrid -treated patients compared with 8.6% treated with SOC.

**Local pain**

In pooled studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 where the medicinal product regimen included recommended preventive analgesia as routinely practiced for extensive dressing changes in burn patients (see section 4.2), pain was reported in 4.0% of patients treated with medicinal product, and in 3.8% of the control patients treated according to SOC.

In early studies where analgesia was provided in medicinal product-treated patients on an on-demand basis, pain was reported in 23.4% of patients treated with medicinal product and in 5.7% in the SOC group.

**Wound infection**

In pooled studies with routine antibacterial soaking of the treatment area before and after medicinal product application (studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 studies), the incidence of wound infection was 5.4% in the medicinal product group and 8.1% in the standard of care group.

In pooled studies which were conducted before implementation of routine antibacterial soaking of the treatment area (studies MW2001-10-03 and MW2002-04-01), The incidence of wound infection was 7.8% in the medicinal product group and 0% in the standard of care group.

**Wound complications**

Wound complications reported include the following: wound deepening, wound desiccation, wound re-opening, graft loss/ graft failure, and local intradermal haematoma.

In pooled phase 2 and 3 studies (MW2001-10-03, MW2002-04-01, MW2004-11-02, MW2005-10-05, MW2008-09-03, and MW2010-03-02) including 300 patients treated with NexoBrid and 195 patients treated with SOC, the following incidence was reported: wound complication 3% in the NexoBrid treated patients and 1.5% in patients treated with SOC, skin graft loss/graft failure 3% in the patients treated with NexoBrid and in 2.5% in patients treated with SOC, wound decomposition 1% in both the NexoBrid and SOC treated patients, local intradermal hematoma 0.7% in NexoBrid treated patients and none in the SOC treated patients.

**Tachycardia**

In pooled phase 2 and 3 studies (MW2001-10-03, MW2002-04-01, MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02) 2.7% of patients experienced tachycardia in temporal proximity to NexoBrid treatment. Alternative causes of tachycardia (e.g. the general burn condition, procedures causing pain, fever and dehydration) should be considered.

**Paediatric population**

There is only limited safety data from the use in the paediatric population. From these data it is expected that the overall safety profile in children 4 years of age and older and in adolescents is similar to the profile in adults. This medicinal product is not indicated for use in patients younger than 18 years (see section 4.2).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**
Treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in patients with deep partial- and/or full-thickness burns within the framework of a clinical study did not result in significantly different safety findings when compared to treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Preparations for treatment of wounds and ulcers, proteolytic enzymes; ATC code: D03BA03.

Mechanism of action

The mixture of enzymes in this medicinal product dissolves burn wound eschar. The specific components responsible for this effect have not been identified. The major constituent is stem bromelain.

Clinical efficacy and safety

During clinical development, a total of 467 patients were treated with the concentrate of proteolytic enzymes enriched in bromelain.

DETECT study (MW2010-03-02) - (Phase 3b)

This study is a multi-center, multi-national, assessor-blinded, randomised, controlled, three-arm study aimed at demonstrating superiority of this medicinal product treatment over Gel Vehicle (placebo) control and standard of care (SOC) treatment, in hospitalised adult subjects with DPT and/or FT thermal burn of >3% TBSA and total burn wounds of no more than 30% TBSA. The mean % TBSA of Target Wound TWs was about 6%.

The analyses were planned in stages: First analysis was performed at the end of the Acute Phase (from baseline until 3 months had passed from last patient reached complete wounds closure) and second analysis was performed after the last patient reached the 12 months follow-up visit.

A total of 175 subjects were randomised (Intend to Treat cohort) in a 3:3:1 ratio (medicinal product:SOC: Gel Vehicle), and 169 subjects were treated. Patients in the SOC treatment arm were treated with surgical and/or non-surgical SOC as per the investigators’ discretion. Overall subject demographics and wound baseline characteristics were comparable across the study arms. The age range in the group treated with this medicinal product was 18 to 75 years, 18 to 72 years in the SOC group and 18 to 70 years in the Gel Vehicle group. Sixteen patients ≥ 65 years old (9.1%) were included in the study. Seven (7) (9.3%) patients in the medicinal product arm, 5 (6.7%) patients in the SOC arm, and 4 (16%) patients in the gel vehicle arm. Mean age in all 3 arms was 41 years, and 65%, 79%, and 60% of subjects were male in the medicinal product, SOC and Gel Vehicle (placebo) arms, respectively. Target Wound (TW) was the burn area to be treated (Eschar Removal) with NexoBrid, SOC or Gel Vehicle. On a patient level, the mean % TBSA of TWs was 6.28% for patients in the medicinal product treatment arm, 5.91% in SOC, and 6.53% in Gel Vehicle (average of 1.7 TWs per subject).

Primary endpoint was incidence of complete (>95%) eschar removal as compared with Gel Vehicle. Secondary endpoints included time to complete eschar removal, reduction in surgical burden, and debridement related blood loss as compared to SOC. Time to complete wound closure, long term cosmesis and function measures by the Modified Vancouver Scar Scale (MVSS) after the 12 months follow-up period were analysed as safety endpoints.

Incidence of Complete Eschar Removal in the DETECT Study
ER=Eschar removal

Compared to SOC, the medicinal product resulted in significant reductions in the incidence of surgical eschar removal (tangential/minor/avulsion/Versajet and/or dermabrasion excision), time to complete eschar removal, and actual blood loss related to eschar removal, as shown below. Similar efficacy of eschar removal was observed in the elderly population.

### Incidence of surgical eschar excision, time to complete eschar removal, and blood loss in the DETECT study

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid (N=75)</th>
<th>Standard of Care (N=75)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of surgical excision (number of subjects)</td>
<td>4.0% (3)</td>
<td>72.0% (54)</td>
<td>p &lt; 0.0001</td>
</tr>
<tr>
<td>Median time to complete eschar removal</td>
<td>1.0 days</td>
<td>3.8 days</td>
<td>p &lt; 0.0001</td>
</tr>
<tr>
<td>Blood loss related to eschar removal$^a$</td>
<td>14.2 ±512.4 mL</td>
<td>814.5 ±1020.3 mL</td>
<td>p &lt; 0.0001</td>
</tr>
</tbody>
</table>

$^a$ Actual Blood Loss calculated using the method described in McCullough 2004: $ABL = \frac{EBV+(Hb_{before}-Hb_{after})}{(Hb_{before}+Hb_{after})/2} + V_{WB} + \frac{5}{3}V_{PC}$

EBV= Estimated blood volume is assumed 70 cm$^3$/kg*weight (kg); (Hb$_{before}$- Hb$_{after}$) = Change in Hb during the eschar removal process; V$_{WB}$= Volume [mL] of whole blood transfused during the eschar removal process; V$_{PC}$= Volume [mL] of packed red blood cells transfused during the eschar removal process.

**Long-term data (12 and 24 months after wound closure)**

The Phase 3 trial (DETECT) included long-term follow up to assess cosmesis and function at 12 and 24 month follow up visits. At 12 months, scar assessment using the Modified Vancouver Scar Score (MVSS) demonstrated comparable outcomes between NexoBrid, SOC, and Gel Vehicle, with mean scores of 3.70, 5.08, and 5.63, respectively. At 24 months, MVSS mean scores were 3.04, 3.30 and 2.93 respectively. Statistical analyses indicated non-inferiority (pre-defined NI margin of 1.9 points) of the medicinal product treatment compared to SOC and showed that treatment with NexoBrid does not have any clinically meaningful deleterious effect on burn scar cosmesis and function compared with the SOC treatment at 24 months after wound closure.

Functionality and quality of life (QOL) measurements at 12 and 24 months were similar across treatment groups. The mean Lower Extremity Functional Scale (LEFS) scores, the mean QuickDASH scores, the range of motion (ROM) evaluations as well as long-term QOL, as measured by EQ-5D VAS (visual analogue scale) and Burn Specific Health Scale-Brief (BSHS-B)were similar among treatment arms.

**Cardiac safety**

In a cardiac safety sub study, the ECGs of up to 150 patients were used to evaluate potential effects of this medicinal product on ECG parameters. The study showed no clear effect of this medicinal product on heart rate, PR interval, QRS duration (cardiac depolarisation), and cardiac repolarisation (QTc). There were no new clinically relevant morphological ECG changes demonstrating a signal of concern.
Study MW2004-02-11 (Phase 3)

This was a randomised, multi-centre, multi-national, open-label, confirmatory phase 3 study evaluating this medicinal product compared to SOC in hospitalised patients with deep partial- and/or full-thickness thermal burns of 5 to 30% TBSA, but with total burn wounds of no more than 30% TBSA. The mean TW area treated in % TBSA was 5.1±3.5 for this medicinal product and 5.2±3.4 for SOC.

Standard of care consisted of primary surgical excision and/or nonsurgical debridement using topical medicinal products to induce maceration and autolysis of eschar according to each study site’s standard practice.

The age range in the group treated with this medicinal product was 4.4 to 55.7 years. The age range in the SOC group was 5.1 to 55.7 years.

The efficacy of eschar removal was evaluated by determining the percentage of wound area left with eschar that required further removal by excision or dermabrasion, and the percentage of wounds requiring such surgical removal. The effect on the timing of eschar removal was evaluated in patients with successful eschar removal (with at least 90% eschar removal in all wounds of a patient combined), by determining the time from injury as well as from informed consent to successful removal.

The co-primary endpoints for the efficacy analysis were:
- the percentage of deep partial thickness wounds requiring excision or dermabrasion, and
- the percentage of deep partial thickness wounds autografted.

The second co-primary endpoint can only be evaluated for deep partial-thickness wounds without full-thickness areas because full-thickness burns always require grafting.

Efficacy data generated in this study for all age groups combined as well as from a subgroup analysis for children and adolescents are summarised below.

<table>
<thead>
<tr>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>106</td>
<td>88</td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>15.1%</td>
<td>62.5%</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded¹ (mean ± SD)</td>
<td>5.5% ± 14.6</td>
<td>52.0% ± 44.5</td>
</tr>
</tbody>
</table>

| **Deep partial-thickness wounds autografted** | | |
| Number of wounds | 106 | 88 | |
| % of wounds autografted | 17.9% | 34.1% | 0.0099 |
| % of wound area autografted (mean ± SD) | 8.4% ± 21.3 | 21.5% ± 34.8 | 0.0054 |

| **Deep partial- and/or full-thickness wounds requiring excision/dermabrasion (surgery)** | | |
| Number of wounds | 163 | 170 | |
| % of wounds requiring surgery | 24.5% | 70.0% | <0.0001 |
| % of wound area excised or dermabraded¹ (mean ± SD) | 13.1% ± 26.9 | 56.7% ± 43.3 | <0.0001 |

| **Time to complete wound closure (time from ICF**)** | | |
| Number of patients² | 70 | 78 | |
| Days to closure of last wound (mean ± SD) | 36.2 ± 18.5 | 28.8 ± 15.6 | 0.0185 |

| **Time to successful eschar removal** | | |
| Number of patients | 67 | 73 | |
| Days (mean ± SD) from injury | 2.2 ± 1.4 | 8.7 ± 5.7 | <0.0001 |
| Days (mean ± SD) from consent | 0.8 ± 0.8 | 6.7 ± 5.8 | <0.0001 |
Patients not reported to have successful eschar removal | 7 | 8
---|---|---

1 Measured at first session, if there was more than one surgery session.
2 All randomised patients for whom data for complete wound closure were available.
*The endpoint can only be evaluated for deep partial-thickness wounds without full-thickness areas because full-thickness burns always require grafting.
** Informed Consent Form

**Long-term data**

A multi-center, non-interventional, assessor-blinded study (MW2012-01-02) evaluated the long-term scar formation and quality of life in adults and children who participated in study MW2004-11-02. A total of 89 subjects were enrolled into the study including 72 adults (>18) and 17 pediatric subjects. Comparison of baseline characteristics between subjects enrolled into MW2012-01-02 and non-enrolled subjects indicated that the enrolled population is representative of the MW-2004-11-02 study population. Scar assessment at 2-5 years using the MVSS demonstrated comparable outcomes between study groups with the mean total overall score of 3.12 and 3.38 for the medicinal product and SOC, respectively (p=0.88).

QOL was assessed in adults using the SF-36 questionnaire. Mean scores for the various parameters were similar in the medicinal product compared to SOC group. The overall physical component score (51.1 and 51.3, respectively) and the overall mental component score (51.8 vs. 49.1, respectively) were comparable between the medicinal product and SOC groups.

**Paediatric population**

Efficacy data generated in study MW2004-11-02 from a subgroup analysis for children and adolescents are summarised below. The available data are limited and this medicinal product should not be used in patients younger than 18 years.

<table>
<thead>
<tr>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>23</td>
<td>22</td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>21.7%</td>
<td>68.2%</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded(^1) (mean ± SD)</td>
<td>7.3% ± 15.7%</td>
<td>64.9% ± 46.4%</td>
</tr>
<tr>
<td><strong>Deep partial-thickness wounds autografted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>23</td>
<td>22</td>
</tr>
<tr>
<td>% of wounds autografted</td>
<td>21.7%</td>
<td>31.8%</td>
</tr>
<tr>
<td>% of wound area autografted (mean ± SD)</td>
<td>6.1% ± 14.7%</td>
<td>24.5% ± 40.6%</td>
</tr>
<tr>
<td><strong>Deep partial- and/or full-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>29</td>
<td>41</td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>20.7%</td>
<td>78%</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded(^1) (mean ± SD)</td>
<td>7.9% ± 17.6%</td>
<td>73.3% ± 41.1%</td>
</tr>
<tr>
<td><strong>Time to complete wound closure (time from ICF</strong>)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients(^2)</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>Days to closure of last wound (mean ± SD)</td>
<td>29.9 ± 14.3</td>
<td>32.1 ± 18.9</td>
</tr>
<tr>
<td><strong>Time to successful eschar removal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>Days (mean ± SD) from injury</td>
<td>1.9 ± 0.8</td>
<td>8.1 ± 6.3</td>
</tr>
<tr>
<td>Days (mean ± SD) from consent</td>
<td>0.9 ± 0.7</td>
<td>6.5 ± 5.9</td>
</tr>
</tbody>
</table>
Patients not reported to have successful eschar removal | 0 | 1

1 Measured at first session, if there was more than one surgery session.
2 All randomised patients for whom data for complete wound closure were available.
* The endpoint can only be evaluated for deep partial-thickness wounds without full-thickness areas because full-thickness burns always require grafting.
** Informed Consent Form

The European Medicines Agency has deferred the obligation to submit the results of studies with this medicinal product in one or more subsets of the paediatric population in the treatment of burns of external body surface (see section 4.2 for information on paediatric use).

Pooled phase 3 studies (studies MW2010-03-02 and MW2004-02-11)

Analysis of wound-closure data
In the DETECT (MW2010-03-02) study, measured mean time to complete wound closure was 29.35 days [SD 19.33] and 27.77 days [SD 19.83] SOC for the medicinal product and SOC treatment arms, respectively (estimated median time: 27 days medicinal product vs. 28 days SOC Non-inferiority = (7 day non-inferiority margin) of NexoBrid treatment arm compared to SOC was established (p=0.0003). Results from pooled wound closure data from both phase 3 studies supported the non-inferiority of the medicinal product compared with SOC based on a 7-day non-inferiority margin. Based on pooled data from the DETECT study and study MW2004-02-11, time to complete wound closure was slightly longer in the medicinal product group than in the SOC group, when calculated using actual data (mean 31.7 days medicinal product vs 29.8 days SOC) or estimated by the Kaplan-Meier method (median 30.0 days vs 25.0 days). Time to complete wound closure was less than 7 days longer with this medicinal product than with SOC (p for non-inferiority=0.0006).

Serious adverse events
Pooled analysis from phase 3 studies (studies MW2010-03-02 and MW2004-02-11 showed that the percentages of patients who experienced serious TEAEs were similar (<2% difference) in the medicinal product (8.5%; 15/177) and SOC (6.7%; 10/149) groups. Serious TEAEs were most frequently reported within the system organ class of Infections and Infestations for both the medicinal product (2.8%) and SOC (2.7%) groups. Only 2 events occurred in more than 1 patient (sepsis occurred in 3 patients in the medicinal product group and 1 patient in the SOC group, bacterial wound infection occurred in 2 patients in the medicinal product group and wound infection occurred in one patient in the SOC group).

Sepsis and bacteraemia related adverse events (serious and non-serious) were reported in similar incidence rate in medicinal product and SOC groups: 2.8% in the medicinal product and 2% in the SOC group.

5.2 Pharmacokinetic properties

Absorption
Exploratory pharmacokinetic analyses were performed in a subset of NexoBrid patients who participated in study MW2008-09-03 and study MW2010-03-02 (DETECT), using the same bioanalytical method. The analyses were performed on serum NexoBrid concentration versus time data and number of treatment applications.

Following topical administration of this medicinal product, evidence of systemic serum exposure was observed in all patients. In general, it appears to be rapidly absorbed, with a median T_{max} value of 4.0 hours (duration of treatment application). NexoBrid exposure was observed with quantifiable serum
concentrations through 48 hours post dose administration. When evaluated, a majority of patients had no quantifiable concentrations after 72 hours.

Exposure results from MW2008-09-03 and MW2010-03-02 studies are listed in the table below. Not all patients had values beyond 4 hours, as such the AUCₜₙₙ values for some patients only cover 4 hours of exposure versus 48 hours of exposure for other patients. In both PK studies there was a statistically significant correlation between serum Cₘₐₓ and AUC₀-₄ values versus dose or %TBSA, suggesting a dose / treatment area dependent increase in exposure. The depth of the medicinal product treated-wound has negligible impact on systemic exposure.

**Summary of PK parameters* measured in all patients from studies MW2008-09-03 and MW2010-03-02**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>N</th>
<th>Tₘₐₓ Median (range) (h)</th>
<th>Cₘₐₓ (ng/mL)</th>
<th>Cₘₐₓ/Dose (ng/mL/g)</th>
<th>AUCₜₙₙ (h*ng/mL)</th>
<th>AUCₜₙₙ/Dose (h*ng/mL/g)</th>
<th>AUCₙₙₙ (h*ng/mL)</th>
<th>AUCₙₙₙ/Dose (h*ng/mL/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study MW2008-09-03</td>
<td>13</td>
<td>4.0 (0.50 - 4.1)</td>
<td>800±640</td>
<td>44.7±36.6</td>
<td>1930±648</td>
<td>103±48.8</td>
<td>2760±2870</td>
<td>149±147</td>
</tr>
<tr>
<td>Study MW2010-03-02</td>
<td>21</td>
<td>4.0 (0.50 - 12)</td>
<td>200±184</td>
<td>16.4±11.9</td>
<td>516±546</td>
<td>39.8±29.7</td>
<td>2500±2330</td>
<td>215±202</td>
</tr>
</tbody>
</table>

*Values are reported as Mean ± SD, which the exception of Tmax, which is reported as Median (Min-Max).

AUCₙₙₙ=area under the curve until last measurable time-point, AUC₀-₄=area under the concentration-time curve from time zero to time 4h, Cₘₐₓ=maximum observed concentration, Tₘₐₓ=time at which the maximum concentration was observed.

**Distribution**

According to a literature report, in plasma, approximately 50% of bromelain binds to the human plasma antiproteinases α₂-macroglobulin and α₁-antichymotrypsin.

**Elimination**

The mean elimination half-life values ranged between 12 and 17 hours, supporting the decreased presence of this medicinal product in serum at 72 hours post treatment.

**Paediatric population**

Pharmacokinetic parameters and the extent of absorption have not been studied in children.

**5.3 Preclinical safety data**

This medicinal product did not cause significant irritation when applied to intact mini-pig skin but caused severe irritation and pain when applied to damaged (abraded) skin.

A single intravenous infusion of a solution prepared from NexoBrid powder in the mini-pig was well tolerated at dose levels of up to 12 mg/kg (achieving plasma levels 2.5fold of the human plasma level after application of the clinical proposed dose to 15% TBSA) but higher doses were overtly toxic, causing haemorrhage in several tissues. Repeated intravenous injections of doses up to 12 mg/kg every third day in the mini-pig were well tolerated for the first three injections but severe clinical signs of toxicity (e.g. haemorrhages in several organs) were observed following the remaining three injections. Such effects could still be seen after the recovery period of 2 weeks.

In embryo-foetal development studies in rats and rabbits, intravenously administered this medicinal product revealed no evidence of indirect and direct toxicity to the developing embryo/foetus. However, maternal exposure levels were considerably lower than those maximally reported in clinical setting (10–500 times lower than human AUC, 3–50 times lower than the human Cₘₐₓ). Since this medicinal product
was poorly tolerated by the parent animals, these studies are not considered relevant for human risk assessment. NexoBrid showed no genotoxic activity when investigated in the standard set of \textit{in vitro} and \textit{in vivo} studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

**Powder**

Ammonium sulphate
Acetic acid

**Gel**

Carbomer 980
disodium phosphate anhydrous
Sodium hydroxide
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

3 years.

From a microbiological point of view and as the enzymatic activity of the product decreases progressively following mixing, the reconstituted product should be used immediately after preparation (within 15 minutes).

6.4 Special precautions for storage

Store and transport refrigerated (2°C-8°C).

Store upright to keep the gel at the bottom of the bottle and in the original package to protect from light.

Do not freeze.

6.5 Nature and contents of container

2 g powder in a vial (glass type II) sealed with a rubber (bromobutyl), stopper and covered with a cap (aluminium), and 20 g gel in a bottle (borosilicate, glass type I), sealed with a rubber stopper and covered with a screw cap (tamper-proof polypropylene).

Pack size of 1 vial of powder and 1 bottle of gel.

6.6 Special precautions for disposal and other handling

There are reports of occupational exposure to bromelain leading to sensitisation. Sensitisation may have occurred due to inhalation of bromelain powder. Allergic reactions to bromelain include anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angioedema, urticaria, and mucosal and gastrointestinal reactions. When mixing this medicinal product powder with the
gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and a surgical mask, is required (see section 4.4). The powder should not be inhaled, see section 4.2 Accidental eye exposure must be avoided. In case of eye exposure, exposed eyes must be irrigated with copious amounts of water for at least 15 minutes. In case of skin exposure, this medicinal product must be rinsed off with water.

**Gel preparation (mixing powder with gel)**

- The powder and gel are sterile. An aseptic technique must be used when mixing the powder with the gel.
- The powder vial must be opened by carefully tearing off the aluminium cap and removing the rubber stopper.
- When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle’s cap. If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
- The powder is then transferred into the corresponding gel bottle.
- Powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained. This usually requires mixing the powder and the gel for 1 to 2 minutes.
- The gel should be prepared at the patient’s bedside.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**

MediWound Germany GmbH  
Hans-Sachs-Strasse 100  
65428 Rüsselsheim  
Germany  
e-mail: info@mediwound.com

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/12/803/001

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18.12.2012  
Date of latest renewal: 12.08.2022

10. **DATE OF REVISION OF THE TEXT**

1. NAME OF THE MEDICINAL PRODUCT

NexoBrid 5 g powder and gel for gel

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One vial contains 5 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 5 g/55 g gel).

The proteolytic enzymes are a mixture of enzymes from the stem of *Ananas comosus* (pineapple plant).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder and gel for gel
The powder is off-white to light tan. The gel is clear and colourless.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

4.2 Posology and method of administration

This medicinal product should only be applied by trained healthcare professionals in specialist burn centres.

**Posology**

5g powder in 50 g gel is applied to a burn wound area of 2.5 % Total Body Surface Area (TBSA) of an adult, with a gel layer thickness of 1.5 to 3 mm.

The gel should not be applied to more than 15% TBSA (see also section 4.4, Coagulopathy).

It should be left in contact with the burn for a duration of 4 hours. There is very limited information on the use of this medicinal product on areas where eschar remained after the first application.

A second and subsequent application is not recommended.

**Special populations**

*Renal impairment*

There is no information on the use in patients with renal impairment. These patients should be carefully monitored.

*Hepatic impairment*

There is no information on the use in patients with hepatic impairment. These patients should be carefully monitored.
Elderly patients
Experience in elderly patients (>65 years) is limited.

Paediatric population
The safety and efficacy of this treatment in children and adolescents younger than 18 years have not yet been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.
This medicinal product is not indicated for use in patients younger than 18 years.

Method of administration

Cutaneous use.

Before use, the powder must be mixed with the gel producing a uniform gel. For instructions on mixing see section 6.6.

Once mixed, the gel should be applied to a clean, keratin-free (blisters removed), and moist wound area.

Each vial, gel, or reconstituted gel should be used for a single use only.

Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to application of the gel as eschar saturated with medicinal products and their remains reduce its activity and decrease its efficacy.

For instructions on preparation of the medicinal product before application, see section 6.6

Precaution to be taken before manipulating or administering the product
When mixing this medicinal product powder with the gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and a surgical mask, is required (see section 4.4). The powder should not be inhaled, see section 6.6.

Preparation of patient and wound area
A total wound area of not more than 15% TBSA can be treated with this medicinal product (see also section 4.4, Coagulopathy).

- Enzymatic debridement is a painful procedure and requires adequate analgesia and/or anesthesia. Pain management must be used as commonly practiced for an extensive dressing change; it should be initiated at least 15 minutes prior to NexoBrid application.
- The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with the gel and prevent eschar removal by it.
- Dressing soaked with an antibacterial solution must be applied for 2 hours.
- All topically applied antibacterial medicinal products must be removed before applying the gel. Remaining antibacterial medicinal products may reduce the activity of NexoBrid by decreasing its efficacy.
- The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser). The paraffin layer must not come into contact with the area to be treated to avoid covering the eschar, thus isolating the eschar from direct contact with the gel.
- To prevent possible irritation of abraded skin by inadvertent contact with the gel and possible bleeding from the wound bed, acute wound areas such as lacerations or escharotomy incisions should be protected by a layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).
- Sterile isotonic sodium chloride 9 mg/ml (0.9%) solution must be sprinkled on the burn wound. The wound must be kept moist during the application procedure.

Application of the gel
• Moisten the area to be treated by sprinkling sterile saline onto the area bordered by the fatty ointment adhesive barrier.
• Within 15 minutes of mixing, the gel must be applied topically to the moistened burn wound, at a thickness of 1.5 to 3 millimetres.
• The wound must then be covered with a sterile occlusive film dressing that adheres to the sterile adhesive barrier material applied as per the instruction above (see Preparation of patient and wound area). The gel must fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing. Gentle pressing of the occlusive dressing at the area of contact with the adhesive barrier will ensure adherence between the occlusive film and the sterile adhesive barrier and achieve complete containment of the gel on the treatment area.
• The dressed wound must be covered with a loose, thick fluffy dressing, held in place with a bandage.
• The dressing must remain in place for 4 hours.

Removal of the gel
• Removal of this medicinal product is a painful procedure and requires adequate analgesia and/or anaesthesia. Appropriate preventive analgesia medicinal products must be administered at least 15 minutes prior to gel application.
• After 4 hours of medicinal product treatment, the occlusive dressing must be removed using aseptic techniques.
• The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
• The dissolved eschar must be removed from the wound by wiping it away with a sterile blunt-edged instrument.
• The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution. The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue. Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
• A dressing soaked with an antibacterial solution must be applied for an additional 2 hours.

Wound care after debridement
• The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.
• Before a permanent skin cover or temporary skin substitute is applied to a freshly enzymatically debrided area, a soaking wet-to-dry dressing must be applied.
• Before application of the grafts or primary dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or scraping to allow dressing adherence.
• Wounds with areas of full-thickness and deep burn should be autografted as soon as possible after the treatment debridement. Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement (see section 4.4).

4.3 Contraindications

Hypersensitivity to the active substance, to pineapples, or papain (see also section 4.4), or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions
The potential of this medicinal product (a protein product) to cause sensitisation should be taken into account. There have been reports of serious allergic reactions including anaphylaxis (with manifestations such as rash, erythema, hypotension, tachycardia) in patients undergoing debridement with the treatment (see section 4.8). In these cases, a causal relationship to NexoBrid was considered possible, but possible allergy to concomitant medicinal products such as opioid analgesics should also be considered. Allergic reactions to inhaled bromelain have been reported in the literature (including anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angioedema, urticaria, and mucosal and gastrointestinal reactions). No occupational hazard was found in a study assessing the amount of airborne particles during NexoBrid Gel preparation. In addition, a delayed-type allergic skin reaction (cheilitis) after longer-term dermal exposure (mouthwash) as well as suspected sensitisation following oral exposure and following repeated occupational airway exposure have been reported. History of allergy needs to be established prior to the administration (see sections 4.3 and 6.6).

In case of skin exposure, medicinal product should be rinsed off with water to reduce the likelihood of skin sensitisation (see section 6.6).

Skin exposure

In case of skin exposure, NexoBrid should be rinsed off with water to reduce the likelihood of skin sensitisation (see section 6.6).

Cross-sensitivity

Cross-sensitivity between bromelain and papain as well as latex proteins (known as latex-fruit syndrome), bee venom, and olive tree pollen has been reported in the literature.

Analgesia

Enzymatic debridement is a painful procedure, and may only be administered after adequate analgesia and/or anesthesia has been established.

Burn wounds for which this medicinal product is not recommended

This treatment is not recommended for use on:
- penetrating burn wounds where foreign materials (e.g. implants, pacemakers, and shunts) and/or vital structures (e.g. larger vessels, eyes) are or could become exposed during debridement.
- chemical burn wounds.
- wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.
- foot burns in diabetic patients and patients with occlusive vascular disease.
- in electrical burns.

Burns for which there is limited or no experience

There is no experience of the use of this medicinal product on: perineal and genital burns.

Use in patients with cardiopulmonary and pulmonary disease

This medicinal product should be used with caution in patients with cardiopulmonary and pulmonary disease, including pulmonary burn trauma and suspected pulmonary burn trauma.

Facial burn wounds
There are literature reports of successful use of this medicinal product in facial burn wounds. Burn surgeons without experience in using this medicinal product should not start using it on facial burn wounds. The treatment must be used with caution in such patients.

**Eye protection**

Direct contact with the eyes must be avoided. Eyes must be carefully protected during treatment of facial burns using fatty ophthalmic ointment on the eyes and adhesive barrier petroleum ointment around to insulate and cover the eyes with occlusive film.

In case of eye exposure, irrigate exposed eyes with copious amounts of water for at least 15 minutes. An ophthalmological exam is recommended prior to and after debridement.

**Systemic absorption**

Concentrate of proteolytic enzymes enriched in bromelain is systemically absorbed from burn wound areas (see section 5.2).

There is limited pharmacokinetic data in patients with TBSA of more than 15%. Due to safety considerations (see also section 4.4, Coagulopathy) this medicinal product should not be applied to more than 15% Total Body Surface Area (TBSA).

**Prevention of wound complications**

General principles of proper burn wound care must be adhered to when using this medicinal product. This includes proper wound cover for the exposed tissue (see section 4.2).

In clinical studies, wounds with visible dermal remnants were allowed to heal by spontaneous epithelialisation. In several cases, adequate healing did not occur, and autografting was required at a later date, leading to delays in wound closure which may be associated with increased risk of wound-related complications. Therefore, wounds with areas of full-thickness and deep burn that will not heal spontaneously by epithelialisation in timely manner should be autografted as soon as possible after NexoBrid debridement (see section 5.1). Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement (see sections 4.2 and 4.8).

As in the case of surgically debrided bed, in order to prevent desiccation and/or formation of pseudoeschar and/or infection, the debrided area should be covered immediately by temporary or permanent skin substitutes or dressings. When applying a permanent skin cover (e.g. autograft) or temporary skin substitute (e.g., allograft) to a freshly enzymatically debrided area, care should be taken to clean and refresh the debrided bed by, e.g., brushing or scraping to allow dressing adherence.

**Coagulopathy**

A reduction of platelet aggregation and plasma fibrinogen levels and a moderate increase in partial thromboplastin and prothrombin times have been reported in the literature as possible effects following oral administration of bromelain. *In vitro* and animal data suggest that bromelain can also promote fibrinolysis. During the clinical development of this medicinal product, there was no indication of an increased bleeding tendency or bleeding at the site of debridement.

The treatment should not be used in patients with uncontrolled disorders of coagulation. It should be used with caution in patients under anticoagulant therapy or other medicinal products affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes, e.g. peptic ulcers and sepsis.

Patients should be monitored for possible signs of coagulation abnormalities and signs of bleeding.

**Clinical monitoring**
In addition to routine monitoring for burn patients (e.g., vital signs, volume/water/electrolyte status, complete blood count, serum albumin and hepatic enzyme levels), patients treated with NexoBrid should be monitored for:
- Rise in body temperature.
- Signs of local and systemic inflammatory and infectious processes.
- Conditions that could be precipitated or worsened by analgesic premedication (e.g., gastric dilatation, nausea and risk of sudden vomiting, constipation) or antibiotic prophylaxis (e.g., diarrhoea).
- Signs of local or systemic allergic reactions.
- Potential effects on haemostasis (see above).

Removal of topically applied antibacterial medicinal products before NexoBrid application

All topically applied antibacterial medicinal products must be removed before applying this medicinal product. Remaining antibacterial medicinal products reduce the activity of this medicinal product by decreasing its efficacy.

Appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and a surgical mask, is required. The powder should not be inhaled.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Medicinal products that affect coagulation

Reduction of platelet aggregation and plasma fibrinogen levels and a moderate increase in partial thromboplastin and prothrombin times have been reported as possible effects following oral administration of bromelain. In vitro and animal data suggest that bromelain can also promote fibrinolysis. Caution and monitoring is therefore needed when prescribing concomitant medicinal products that affect coagulation. (see also section 4.4.).

CYP2C8 and CYP 2C9 substrates

The medicinal product, when absorbed, is an inhibitor of cytochrome P 450 2C8 (CYP2C8) and P450 2C9 (CYP2C9). This should be taken into account if this medicinal product is used in patients receiving CYP2C8 substrates (including amiodarone, amodiaquine, chloroquine, fluvastatin, paclitaxel, pioglitazone, repaglinide, rosiglitazone, sorafenib and torasemide) and CYP2C9 substrates (including ibuprofen, tolbutamide, glipizide, losartan, celecoxib, warfarin, and phenytoin).

Topical antibacterial medicinal products

Topically applied antibacterial medicinal products (e.g. silver sulfadiazine or povidone iodine) may decrease the efficacy of this medicinal product (see section 4.4).

Fluorouracil and vincristine

Bromelain may enhance the actions of fluorouracil and vincristine. Patients should be monitored for increased toxicity.

ACE inhibitors

Bromelain may enhance the hypotensive effect of ACE inhibitors, causing larger decreases in blood pressure than expected. Blood pressure should be monitored in patients receiving ACE inhibitors.

Benzodiazepines, barbiturates, narcotics and antidepressants
Bromelain may increase drowsiness caused by some medicinal products (e.g., benzodiazepines, barbiturates, narcotics and antidepressants). This should be taken into account when dosing such products.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data from the use of concentrate of proteolytic enzymes enriched in bromelain in pregnant women.
Animal studies are insufficient to properly assess the potential of this medicinal product to interfere with embryonal/foetal development (see section 5.3).

Since the safe use of medicinal product during pregnancy has not yet been established, it is not recommended during pregnancy.

Breastfeeding

It is unknown whether concentrate of proteolytic enzymes enriched in bromelain or its metabolites are excreted in human milk. A risk to new-borns/infants cannot be excluded. Breast-feeding should be discontinued at least 4 days from NexoBrid application initiation.

Fertility

No studies were performed to assess the effects of this medicinal product on fertility.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions are transient pyrexia/hyperthermia and local pain (incidence of 15.2 % and 4.0% respectively)

Tabulated list of adverse reactions

The following definitions apply to the frequency terminology used hereafter: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

The frequencies of the adverse reactions presented below reflect the use of this medicinal product to remove eschar from deep partial- or full-thickness burns in a regimen with local antibacterial prophylaxis, recommended analgesia, as well as coverage of the wound area after application of the treatment for 4 hours with an occlusive dressing for containment of NexoBrid on the wound.

*Infections and infestations
Common: Wound infection*

Immune system disorders
Common: Non serious allergic reactions such as rash
Not known: Serious allergic reactions including anaphylaxis *

Cardiac disorders
Common: Tachycardia*

Skin and subcutaneous tissue disorders/
Common: Wound complication*

General disorders and administration site conditions
Very common: Pyrexia/hyperthermia*
Common: Local pain*

*see Description of selected adverse reactions below.

see section 4.4.

Description of selected adverse reactions

Pyrexia/hyperthermia
In pooled studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 with routine antibacterial soaking of the treatment area before and after this medicinal product application (see section 4.2), pyrexia or hyperthermia was reported in 15.2% of patients treated with it and in 11.3% of the control patients treated according to standard of care (SOC).
In early studies without antibacterial soaking (Studies MW2001-10-03 and MW2002-04-01), pyrexia or hyperthermia was reported in 35.1% of NexoBrid -treated patients compared with 8.6% treated with SOC.

Local pain
In pooled studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 where the medicinal product regimen included recommended preventive analgesia as routinely practiced for extensive dressing changes in burn patients (see section 4.2), pain was reported in 4.0% of patients treated with medicinal product, and in 3.8% of the control patients treated according to SOC.
In early studies where analgesia was provided in medicinal product-treated patients on an on-demand basis, pain was reported in 23.4% of patients treated with medicinal product and in 5.7% in the SOC group.

Wound infection
In pooled studies with routine antibacterial soaking of the treatment area before and after medicinal product application (studies MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02 studies), the incidence of wound infection was 5.4% in the medicinal product group and 8.1% in the standard of care group.
In pooled studies which were conducted before implementation of routine antibacterial soaking of the treatment area (studies MW2001-10-03 and MW2002-04-01), The incidence of wound infection was 7.8% in the medicinal product group and 0% in the standard of care group.

Wound complications
Wound complications reported include the following: wound deepening, wound desiccation, wound re-opening, graft loss/graft failure, and local intradermal haematoma.
In pooled phase 2 and 3 studies (MW2001-10-03, MW2002-04-01, MW2004-11-02, MW2005-10-05, MW2008-09-03, and MW2010-03-02) including 300 patients treated with NexoBrid and 195 patients treated with SOC, the following incidence was reported: wound complication 3% in the NexoBrid treated patients and 1.5% in patients treated with SOC, skin graft loss/graft failure 3% in the patients treated with NexoBrid and in 2.5% in patients treated with SOC, wound decomposition 1% in both the NexoBrid and SOC treated patients, local intradermal hematoma 0.7% in NexoBrid treated patients and none in the SOC treated patients.

Tachycardia
In pooled phase 2 and 3 studies (MW2001-10-03, MW2002-04-01, MW2004-11-02, MW2005-10-05, MW2008-09-03 and MW2010-03-02) 2.7% of patients experienced tachycardia in temporal proximity to
NexoBrid treatment. Alternative causes of tachycardia (e.g. the general burn condition, procedures causing pain, fever and dehydration) should be considered.

**Paediatric population**

There is only limited safety data from the use in the paediatric population. From these data it is expected that the overall safety profile in children 4 years of age and older and in adolescents is similar to the profile in adults. This medicinal product is not indicated for use in patients younger than 18 years (see section 4.2).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

Treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:5 (0.16g per g of mixed gel) in patients with deep partial- and/or full-thickness burns within the framework of a clinical study did not result in significantly different safety findings when compared to treatment with concentrate of proteolytic enzymes enriched in bromelain prepared in a powder:gel ratio of 1:10 (0.09 g per 1g of mixed gel).

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Preparations for treatment of wounds and ulcers, proteolytic enzymes; ATC code: D03BA03.

**Mechanism of action**

The mixture of enzymes in this medicinal product dissolves burn wound eschar. The specific components responsible for this effect have not been identified. The major constituent is stem bromelain.

**Clinical efficacy and safety**

During clinical development, a total of 467 patients were treated with the concentrate of proteolytic enzymes enriched in bromelain.

**DETECT study (MW2010-03-02)- (Phase 3b)**

This study is a multi-center, multi-national, assessor-blinded, randomised, controlled, three-arm study aimed at demonstrating superiority of this medicinal product treatment over Gel Vehicle (placebo) control and standard of care (SOC) treatment, in hospitalised adult subjects with DPT and/or FT thermal burn of >3% TBSA and total burn wounds of no more than 30% TBSA. The mean % TBSA of Target Wound TWs was about 6%.

The analyses were planned in stages: First analysis was performed at the end of the Acute Phase (from baseline until 3 months had passed from last patient reached complete wounds closure) and second analysis was performed after the last patient reached the 12 months follow-up visit.

A total of 175 subjects were randomised (Intend to Treat cohort) in a 3:3:1 ratio (this medicinal product:SOC: Gel Vehicle), and 169 subjects were treated. Patients in the SOC treatment arm were treated with surgical and/or non-surgical SOC as per the investigators’ discretion.
Overall subject demographics and wound baseline characteristics were comparable across the study arms. The age range in the group treated with this medicinal product was 18 to 75 years, 18 to 72 years in the SOC group and 18 to 70 years in the Gel Vehicle group. Sixteen patients ≥ 65 years old (9,1%) were included in the study. Seven (7) (9.3%) patients in the medicinal product arm, 5 (6.7%) patients in the SOC arm, and 4 (16%) patients in the gel vehicle arm. Mean age in all 3 arms was 41 years, and 65%, 79%, and 60% of subjects were male in the medicinal product, SOC and Gel Vehicle (placebo) arms, respectively. Target Wound (TW) was the burn area to be treated (Eschar Removal) with NexoBrid, SOC or Gel Vehicle. On a patient level, the mean % TBSA of TWs was 6.28% for patients in the medicinal product treatment arm, 5.91% in SOC, and 6.53% in Gel Vehicle (average of 1.7 TWs per subject).

Primary endpoint was incidence of complete (>95%) eschar removal as compared with Gel Vehicle. Secondary endpoints included time to complete eschar removal, reduction in surgical burden, and debridement related blood loss as compared to SOC. Time to complete wound closure, long term cosmesis and function measures by the Modified Vancouver Scar Scale (MVSS) after the 12 months follow-up period were analysed as safety endpoints.

### Incidence of Complete Eschar Removal in the DETECT Study

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid (ER/N)</th>
<th>Gel Vehicle (ER/N)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of complete eschar removal</td>
<td>93.3% (70/75)</td>
<td>4.0% (1/25)</td>
<td>p &lt; 0.0001</td>
</tr>
</tbody>
</table>

ER=Eschar removal

Compared to SOC, the medicinal product resulted in significant reductions in the incidence of surgical eschar removal (tangential/minor/avulsion/Versajet and/or dermabrasion excision), time to complete eschar removal, and actual blood loss related to eschar removal, as shown below. Similar efficacy of eschar removal was observed in the elderly population.

### Incidence of surgical eschar excision, time to complete eschar removal, and blood loss in the DETECT study

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid (N=75)</th>
<th>Standard of Care (N=75)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of surgical excision (number of subjects)</td>
<td>4.0% (3)</td>
<td>72.0% (54)</td>
<td>p &lt; 0.0001</td>
</tr>
<tr>
<td>Median time to complete eschar removal</td>
<td>1.0 days</td>
<td>3.8 days</td>
<td>p &lt; 0.0001</td>
</tr>
<tr>
<td>Blood loss related to eschar removal(^a)</td>
<td>14.2 ±512.4 mL</td>
<td>814.5 ±1020.3 mL</td>
<td>p &lt; 0.0001</td>
</tr>
</tbody>
</table>

\(^a\) Actual Blood Loss calculated using the method described in McCullough 2004: 

\[ ABL = \frac{EBV \times (Hb_{before} - Hb_{after})}{(Hb_{before} + Hb_{after})/2} + V_{WB} + \frac{5}{3} V_{PC} \]

EBV= Estimated blood volume is assumed 70 cm\(^3\)/kg*weight (kg); (Hb\(_{before}\)-Hb\(_{after}\)) = Change in Hb during the eschar removal process; V\(_{WB}\)= Volume [mL] of whole blood transfused during the eschar removal process; V\(_{PC}\)= Volume [mL] of packed red blood cells transfused during the eschar removal process.

**Long-term data (12 and 24 months after wound closure)**

The Phase 3 trial (DETECT) included long-term follow up to assess cosmesis and function at 12 and 24 month follow up visits. At 12 months, scar assessment using the Modified Vancouver Scar Score (MVSS) demonstrated comparable outcomes between the NexoBrid, SOC, and Gel Vehicle, with mean scores of 3.70, 5.08, and 5.63, respectively. At 24 months, MVSS mean scores were 3.04, 3.30 and 2.93 respectively. Statistical analyses indicated non-inferiority (pre-defined NI margin of 1.9 points) of the medicinal product.
treatment compared to SOC and showed that treatment with NexoBrid does not have any clinically meaningful deleterious effect on burn scar cosmescis and function compared with the SOC treatment at 24 months after wound closure.

Functionality and quality of life (QOL) measurements at 12 and 24 months were similar across treatment groups. The mean Lower Extremity Functional Scale (LEFS) scores, the mean QuickDASH scores, the range of motion (ROM) evaluations as well as long-term QOL, as measured by EQ-5D VAS (visual analogue scale) and Burn Specific Health Scale-Brief (BSHS-B) were similar among treatment arms.

Cardiac safety:
In a cardiac safety sub study, the ECGs of up to 150 patients were used to evaluate potential effects of this medicinal product on ECG parameters. The study showed no clear effect of this medicinal product on heart rate, PR interval, QRS duration (cardiac depolarisation), and cardiac repolarisation (QTc). There were no new clinically relevant morphological ECG changes demonstrating a signal of concern.

Study MW2004-02-11 (Phase 3)
This was a randomised, multi-centre, multi-national, open-label, confirmatory phase 3 study evaluating this medicinal product compared to SOC in hospitalised patients with deep partial- and/or full-thickness thermal burns of 5 to 30% TBSA, but with total burn wounds of no more than 30% TBSA. The mean TW area treated in % TBSA was 5.1±3.5 for this medicinal product and 5.2±3.4 for SOC.

Standard of care consisted of primary surgical excision and/or nonsurgical debridement using topical medicinal products to induce maceration and autolysis of eschar according to each study site’s standard practice.

The age range in the group treated with the medicinal product was 4.4 to 55.7 years. The age range in the SOC group was 5.1 to 55.7 years.

The efficacy of eschar removal was evaluated by determining the percentage of wound area left with eschar that required further removal by excision or dermabrasion, and the percentage of wounds requiring such surgical removal.

The effect on the timing of eschar removal was evaluated in patients with successful eschar removal (with at least 90% eschar removal in all wounds of a patient combined), by determining the time from injury as well as from informed consent to successful removal.

The co-primary endpoints for the efficacy analysis were:
- the percentage of deep partial thickness wounds requiring excision or dermabrasion, and
- the percentage of deep partial thickness wounds autografted.

The second co-primary endpoint can only be evaluated for deep partial-thickness wounds without full-thickness areas because full-thickness burns always require grafting.

Efficacy data generated in this study for all age groups combined as well as from a subgroup analysis for children and adolescents are summarised below.

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>106</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>15.1%</td>
<td>62.5%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded (mean ± SD)</td>
<td>5.5% ± 14.6</td>
<td>52.0% ± 44.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Deep partial-thickness wounds autografted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>106</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>% of wounds autografted</td>
<td>17.9%</td>
<td>34.1%</td>
<td>0.0099</td>
</tr>
<tr>
<td>% of wound area autografted (mean ± SD)</td>
<td>8.4% ± 21.3</td>
<td>21.5% ± 34.8</td>
<td>0.0054</td>
</tr>
<tr>
<td><strong>Deep partial- and/or full-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Number of wounds

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of wounds</td>
<td>163</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>24.5%</td>
<td>70.0%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded&lt;sup&gt;1&lt;/sup&gt; (mean ± SD)</td>
<td>13.1% ± 26.9</td>
<td>56.7% ± 43.3</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

### Time to complete wound closure (time from ICF**)

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients&lt;sup&gt;2&lt;/sup&gt;</td>
<td>70</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Days to closure of last wound (mean ± SD)</td>
<td>36.2 ± 18.5</td>
<td>28.8 ± 15.6</td>
<td>0.0185</td>
</tr>
</tbody>
</table>

### Time to successful eschar removal

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>67</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Days (mean ± SD) from injury</td>
<td>2.2 ± 1.4</td>
<td>8.7 ± 5.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Days (mean ± SD) from consent</td>
<td>0.8 ± 0.8</td>
<td>6.7 ± 5.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Patients not reported to have successful eschar removal</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> Measured at first session, if there was more than one surgery session.

<sup>2</sup> All randomised patients for whom data for complete wound closure were available.

*The endpoint can only be evaluated for deep partial-thickness wounds without full-thickness areas because full-thickness burns always require grafting.

** Informed Consent Form

### Long-term data


A total of 89 subjects were enrolled into the study including 72 adults (>18) and 17 pediatric subjects. Comparison of baseline characteristics between subjects enrolled into MW2012-01-02 and non-enrolled subjects indicated that the enrolled population is representative of the MW-2004-11-02 study population.

Scar assessment at 2-5 years using the MVSS demonstrated comparable outcomes between study groups with the mean total overall score of 3.12 and 3.38 for the medicinal product and SOC, respectively (p=0.88).

QOL was assessed in adults using the SF-36 questionnaire. Mean scores for the various parameters were similar in the medicinal product compared to SOC group. The overall physical component score (51.1 and 51.3, respectively) and the overall mental component score (51.8 vs. 49.1, respectively) were comparable between the medicinal product and SOC groups.

### Paediatric population

Efficacy data generated in study MW2004-11-02 from a subgroup analysis for children and adolescents are summarised below. The available data are limited and this medicinal product should not be used in patients younger than 18 years.

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>23</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>% of wounds requiring surgery</td>
<td>21.7%</td>
<td>68.2%</td>
<td>0.0017</td>
</tr>
<tr>
<td>% of wound area excised or dermabraded&lt;sup&gt;1&lt;/sup&gt; (mean ± SD)</td>
<td>7.3% ± 15.7%</td>
<td>64.9% ± 46.4%</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial-thickness wounds autografted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of wounds</td>
<td>23</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>% of wounds autografted</td>
<td>21.7%</td>
<td>31.8%</td>
<td>0.4447</td>
</tr>
<tr>
<td>% of wound area autografted (mean ± SD)</td>
<td>6.1% ± 14.7%</td>
<td>24.5% ± 40.6%</td>
<td>0.0754</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>NexoBrid</th>
<th>SOC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep partial- and/or full-thickness wounds requiring excision/dermabrasion (surgery)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The European Medicines Agency has deferred the obligation to submit the results of studies with this medicinal product in one or more subsets of the paediatric population in the treatment of burns of external body surface (see section 4.2 for information on paediatric use).

Pooled phase 3 studies (studies MW2010-03-02 and MW2004-02-11)

Analysis of wound-closure data

In the DETECT (MW2010-03-02) study, measured mean time to complete wound closure was 29.35 days [SD 19.33] and 27.77 days [SD 19.83] SOC for the medicinal product and SOC treatment arms, respectively (estimated median time: 27 days medicinal product vs. 28 days SOC Non-inferiority = (7 day non-inferiority margin) of NexoBrid treatment arm compared to SOC was established (p=0.0003).

Results from pooled wound closure data from both phase 3 studies supported the non-inferiority of the medicinal product compared with SOC based on a 7-day non-inferiority margin. Based on pooled data from the DETECT study and study MW2004-02-11, time to complete wound closure was slightly longer in the medicinal product group than in the SOC group, when calculated using actual data (mean 31.7 days medicinal product vs 29.8 days SOC) or estimated by the Kaplan-Meier method (median 30.0 days vs 25.0 days). Time to complete wound closure was less than 7 days longer with this medicinal product than with SOC (p for non-inferiority=0.0006).

Serious adverse events

Pooled analysis from phase 3 studies (studies MW2010-03-02 and MW2004-02-11) showed that the percentages of patients who experienced serious TEAEs were similar (<2% difference) in the medicinal product (8.5%; 15/177) and SOC (6.7%; 10/149) groups.

Serious TEAEs were most frequently reported within the system organ class of Infections and Infestations for both the medicinal product (2.8%) and SOC (2.7%) groups.

Only 2 events occurred in more than 1 patient (sepsis occurred in 3 patients in the medicinal product group and 1 patient in the SOC group, bacterial wound infection occurred in 2 patients in the medicinal product group and wound infection occurred in one patient in the SOC group).

Sepsis and bacteraemia related adverse events (serious and non-serious) were reported in similar incidence rate in medicinal product and SOC groups: 2.8% in the medicinal product and 2% in the SOC group.
5.2 Pharmacokinetic properties

Absorption

Exploratory pharmacokinetic analyses were performed in a subset of NexoBrid patients who participated in study MW2008-09-03 and study MW2010-03-02 (DETECT), using the same bioanalytical method. The analyses were performed on serum NexoBrid concentration versus time data and number of treatment applications.

Following topical administration of this medicinal product, evidence of systemic serum exposure was observed in all patients. In general, it appears to be rapidly absorbed, with a median T\text{max} value of 4.0 hours (duration of treatment application). NexoBrid exposure was observed with quantifiable serum concentrations through 48 hours post dose administration. When evaluated, a majority of patients had no quantifiable concentrations after 72 hours.

Exposure results from MW2008-09-03 and MW2010-03-02 studies are listed in the table below. Not all patients had values beyond 4 hours, as such the AUC\text{last} values for some patients only cover 4 hours of exposure versus 48 hours of exposure for other patients. In both PK studies there was a statistically significant correlation between serum C\text{max} and AUC\text{0-4} values versus dose or %TBSA, suggesting a dose/treatment area dependent increase in exposure. The depth of the medicinal product treated-wound has negligible impact on systemic exposure.

Summary of PK parameters* measured in all patients from studies MW2008-09-03 and MW2010-03-02

<table>
<thead>
<tr>
<th>Study ID</th>
<th>N</th>
<th>T\text{max} Median (range) (h)</th>
<th>C\text{max} (ng/mL)</th>
<th>C\text{max}/Dose (ng/mL/g)</th>
<th>AUC\text{0-4} (h*ng/mL)</th>
<th>AUC\text{0-4}/Dose (h*ng/mL/g)</th>
<th>AUC\text{last} (h*ng/mL)</th>
<th>AUC\text{last}/Dose (h*ng/mL/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study MW2008-09-03</td>
<td>13</td>
<td>4.0 (0.50 - 4.1)</td>
<td>800±640</td>
<td>44.7±36.6</td>
<td>1930±648\textsuperscript{a}</td>
<td>103±48.8\textsuperscript{a}</td>
<td>2760±2870</td>
<td>149±147</td>
</tr>
<tr>
<td>Study MW2010-03-02</td>
<td>21</td>
<td>4.0 (0.50 - 12)</td>
<td>200±184 (Min=30.7)</td>
<td>16.4±11.9</td>
<td>516±546</td>
<td>39.8±29.7</td>
<td>2500±2330</td>
<td>215±202</td>
</tr>
</tbody>
</table>

*Values are reported as Mean ± SD, which the exception of T\text{max}, which is reported as Median (Min-Max).

AUC\text{last}=area under the curve until last measurable time-point, AUC\text{0-4}=area under the concentration-time curve from time zero to time 4h, C\text{max}=maximum observed concentration, T\text{max}=time at which the maximum concentration was observed

Distribution

According to a literature report, in plasma, approximately 50% of bromelain binds to the human plasma antiproteinases α\text{2}-macroglobulin and α\text{1}-antichymotrypsin.

Elimination

The mean elimination half-life values ranged between 12 and 17 hours, supporting the decreased presence of this medicinal product in serum at 72 hours post treatment.

Paediatric population

Pharmacokinetic parameters and the extent of absorption have not been studied in children.

5.3 Preclinical safety data

This medicinal product did not cause significant irritation when applied to intact mini-pig skin but caused severe irritation and pain when applied to damaged (abraded) skin.
A single intravenous infusion of a solution prepared from NexoBrid powder in the mini-pig was well tolerated at dose levels of up to 12 mg/kg (achieving plasma levels 2.5 fold of the human plasma level after application of the clinical proposed dose to 15% TBSA) but higher doses were overtly toxic, causing haemorrhage in several tissues. Repeated intravenous injections of doses up to 12 mg/kg every third day in the mini-pig were well tolerated for the first three injections but severe clinical signs of toxicity (e.g. haemorrhages in several organs) were observed following the remaining three injections. Such effects could still be seen after the recovery period of 2 weeks.

In embryo-foetal development studies in rats and rabbits, intravenously administered this medicinal product revealed no evidence of indirect and direct toxicity to the developing embryo/foetus. However, maternal exposure levels were considerably lower than those maximally reported in clinical setting (10–500 times lower than human AUC, 3–50 times lower than the human Cmax). Since this medicinal product was poorly tolerated by the parent animals, these studies are not considered relevant for human risk assessment. NexoBrid showed no genotoxic activity when investigated in the standard set of in vitro and in vivo studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Powder
Ammonium sulphate
Acetic acid

Gel
Carbomer 980
disodium phosphate anhydrous
Sodium hydroxide
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

3 years.

From a microbiological point of view and as the enzymatic activity of the product decreases progressively following mixing, the reconstituted product should be used immediately after preparation (within 15 minutes).

6.4 Special precautions for storage

Store and transport refrigerated (2°C-8°C).

Store upright to keep the gel at the bottom of the bottle and in the original package to protect from light.

Do not freeze.

6.7 Nature and contents of container
5 g powder in a vial (glass type II) sealed with a rubber (bromobutyl), stopper and covered with a cap (aluminium), and 50 g gel in a bottle (borosilicate, glass type I), sealed with a rubber stopper and covered with a screw cap (tamper-proof polypropylene).

Pack size of 1 vial of powder and 1 bottle of gel.

6.6 Special precautions for disposal and other handling

There are reports of occupational exposure to bromelain leading to sensitisation. Sensitisation may have occurred due to inhalation of bromelain powder. Allergic reactions to bromelain include anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angioedema, urticaria, and mucosal and gastrointestinal reactions. When mixing this medicinal product powder with the gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and a surgical mask, is required (see section 4.4). The powder should not be inhaled, see section 4.2.

Accidental eye exposure must be avoided. In case of eye exposure, exposed eyes must be irrigated with copious amounts of water for at least 15 minutes. In case of skin exposure, this medicinal product must be rinsed off with water.

Gel preparation (mixing powder with gel)

- The powder and gel are sterile. An aseptic technique must be used when mixing the powder with the gel.
- The powder vial must be opened by carefully tearing off the aluminium cap and removing the rubber stopper.
- When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle’s cap. If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
- The powder is then transferred into the corresponding gel bottle.
- Powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained. This usually requires mixing the powder and the gel for 1 to 2 minutes.
- The gel should be prepared at the patient’s bedside.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18.12.2012

Date of latest renewal: 12.08.2022
10. **DATE OF REVISION OF THE TEXT**

ANNEX II

A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

MediWound Ltd.
42 Hayarkon St.
81227 Yavne
Israel

Name and address of the manufacturer responsible for batch release

Diapharm GmbH & Co. KG
Am Mittelhafen 56
48155 Münster
Germany

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic safety update reports (PSURs)
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

• An updated RMP should be submitted:
  • At the request of the European Medicines Agency;
  • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

• Additional risk minimisation measures
Prior to launch in each Member State, the Marketing Authorisation Holder MAH shall agree the content and format of the educational programme with the national competent authority. The Marketing Authorisation Holder (MAH) should ensure that, at launch, all Healthcare Professionals in specialist burn centres who are expected to use and/or prescribe NexoBrid receive a specific training and are provided with an Educational pack.
MAH should undertake a controlled distribution of NexoBrid to ensure that the product is not available for use at a centre until at least one surgeon at the centre has received formal training in the use of NexoBrid. This is in addition to the educational material which all potential users should receive.

- **The educational pack should contain the following:**
  - Summary of Product Characteristics and Patient Information Leaflet
  - Healthcare Professional information pack

The Healthcare Professional information pack should be a step by step treatment guide that includes information on the following key elements:

- **Before prescribing NexoBrid**
  - The limitation of the total area than can be treated to 15% TBSA
  - The risk of allergic reaction and of cross reactivity and the contraindication in patients allergic to pineapple and papain or to previous application of the product
  - The risk of increased mortality in patients with cardiopulmonary diseases

- **Before applying NexoBrid**
  - The need for pain management
  - The need for wound cleansing and preparation before treatment with
    - Application of a dressing soaked with an antibacterial solution for two hours before NexoBrid application
    - Protection of surrounding skin areas
  - The method of preparation of NexoBrid and of its application to wound area

- **After applying NexoBrid**
  - The removal of NexoBrid and of dissolved eschar
  - The wound assessment and the warning against any repeat treatment
  - The wound management after NexoBrid treatment with
    - Application of a dressing soaked with an antibacterial solution for two hours
    - Performance of grafting procedures as soon as possible after debridement
  - The fact that NexoBrid may cause an allergic reaction, an increased tendency to bleed and severe local irritation and that patients should be monitored for signs or symptoms of these
  - The fact that patients should be monitored for signs and symptoms of wound and systemic infections
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
1. NAME OF THE MEDICINAL PRODUCT

NexoBrid 2 g powder and gel for gel
concentrate of proteolytic enzymes enriched in bromelain

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One vial contains 2 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to
0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 2 g/22 g gel).

3. LIST OF EXCIPIENTS

Excipients for the powder: Acetic acid, ammonium sulphate.
Excipients for the gel: Carbomer 980, disodium phosphate anhydrous, sodium hydroxide, water for
injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and gel for gel

1 vial of 2 g powder
1 bottle of 20 g of gel

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Powder and gel to be mixed before application.

Read the package leaflet before use.

For single use only.

Cutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF
THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2°C-8°C).
Do not freeze.
Store in the original package in order to protect from light. Store upright.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS**

NexoBrid powder (vial)

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>NexoBrid 2 g powder for gel concentrate of proteolytic enzymes enriched in bromelain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>One vial contains 2 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 2 g/22 g gel).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excipients: Acetic acid, ammonium sulphate.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for gel 2 g</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder and gel to be mixed before application.</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>For single use only.</td>
</tr>
<tr>
<td>Cutaneous use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

| 9. SPECIAL STORAGE CONDITIONS |
Store and transport refrigerated (2°C-8°C).

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/12/803/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA
### PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS

Gel for NexoBrid powder

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel for NexoBrid 2 g</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrate of proteolytic enzymes enriched in bromelain: 0.09 g/g (or 2 g/22 g gel) after mixing.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excipients: Carbomer 980, disodium phosphate anhydrous, sodium hydroxide, water for injections.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel</td>
</tr>
<tr>
<td>20 g</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder and gel to be mixed before application.</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>For single use only.</td>
</tr>
<tr>
<td>Cutaneous use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Store and transport refrigerated (2°C-8°C).</td>
</tr>
<tr>
<td>Do not freeze.</td>
</tr>
</tbody>
</table>
Store in the original package in order to protect from light. Store upright.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

NexoBrid 5 g powder and gel for gel
concentrate of proteolytic enzymes enriched in bromelain

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One vial contains 5 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to
0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 5 g/55 g gel).

3. LIST OF EXCIPIENTS

Excipients for the powder: Acetic acid, ammonium sulphate.
Excipients for the gel: Carbomer 980, disodium phosphate anhydrous, sodium hydroxide, water for
injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and gel for gel

1 vial of 5 g powder
1 bottle of 50 g of gel

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Powder and gel to be mixed before application.

Read the package leaflet before use.

For single use only.

Cutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2°C-8°C).
Do not freeze.
Store in the original package in order to protect from light. Store upright.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS

NexoBrid powder (vial)

1. NAME OF THE MEDICINAL PRODUCT

NexoBrid 5 g powder for gel concentrate of proteolytic enzymes enriched in bromelain

2. STATEMENT OF ACTIVE SUBSTANCE

One vial contains 5 g of concentrate of proteolytic enzymes enriched in bromelain, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing (or 5 g/55 g gel).

3. LIST OF EXCIPIENTS

Excipients: Acetic acid, ammonium sulphate.

4. PHARMACEUTICAL FORM AND CONTENT

Powder for gel
5 g

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Powder and gel to be mixed before application.

Read the package leaflet before use.

For single use only.

Cutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2°C-8°C).

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING UNITS

Gel for NexoBrid powder

1. NAME OF THE MEDICINAL PRODUCT

Gel for NexoBrid 5 g

2. STATEMENT OF ACTIVE SUBSTANCE

Concentrate of proteolytic enzymes enriched in bromelain: 0.09 g/g (or 5 g/55 g gel) after mixing.

3. LIST OF EXCIPIENTS

Excipients: Carbomer 980, disodium phosphate anhydrous, sodium hydroxide, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Gel
50 g

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Powder and gel to be mixed before application.

Read the package leaflet before use.

For single use only.

Cutaneous use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
Store and transport refrigerated (2°C-8°C).
Do not freeze.
Store in the original package in order to protect from light. Store upright.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF MARKETING AUTHORISATION HOLDER

MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/803/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS FOR USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA
B. PACKAGE LEAFLET
Package leaflet: Information for the user

NexoBrid 2 g powder and gel for gel
concentrate of proteolytic enzymes enriched in bromelain

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What NexoBrid is and what it is used for
2. What you need to know before NexoBrid is used
3. How NexoBrid is used
4. Possible side effects
5. How NexoBrid is stored
6. Contents of the pack and other information

1. What NexoBrid is and what it is used for

What NexoBrid is
NexoBrid contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is produced from an extract from the stem of the pineapple plant.

What NexoBrid is used for
NexoBrid is used in adult patients to remove burnt tissue from deep or partially deep burn wounds of the skin.
Using NexoBrid may reduce the need for, or the extent of, surgical removal of burnt tissue and/or skin transplantation.

2. What you need to know before NexoBrid is used

NexoBrid must not be used:
- if you are allergic to bromelain
- if you are allergic to pineapples
- if you are allergic to papain
- if you are allergic to any of the other ingredients of the powder or gel (listed in section 6).

Warnings and precautions
Talk to your doctor or nurse before NexoBrid is used if:
- you have a heart disease;
- you have diabetes;
- you have an active peptic ulcer in the stomach,
- you have a vascular disease (with vascular occlusion);
- you have implants or a pacemaker or a vascular shunt;
- you have problems with bleeding or if you take blood-thinners;
- your wound(s) came into contact with chemicals or other hazardous substances;
- you have a lung disease;
- your lung has been, or may have been damaged by inhalation of smoke;
- you are allergic to latex, bee stings, or olive tree pollen. If so, you may also experience allergic reactions to NexoBrid.

Allergic reactions can cause, for example, breathing difficulties, swelling of the skin, hives, other skin reactions, redness of the skin, low blood pressure, fast heart rate and abdominal discomfort, or a combination of such effects. If you notice any of these signs or symptoms, inform your doctor or caregiver immediately.

Allergic reactions can be severe and require medical treatment.

In case of skin contact, rinse NexoBrid off with water. This is to make it less likely that you develop an allergic reaction to NexoBrid.

The use of NexoBrid to remove burnt tissue may lead to fever, to wound inflammation or wound infection, and possibly to general infection. You may be checked regularly for these conditions. You may receive medicines to prevent or treat infections.

NexoBrid may reduce the ability of your blood to form clots, which increases the risk of bleeding. NexoBrid should be used with caution if you are treated with medicines that reduce your blood’s ability to form clots (so-called blood-thinners) or if you have a general tendency to bleed, a stomach ulcer, blood poisoning, or another condition that could cause you to bleed. After treatment with NexoBrid your doctor may check your blood coagulation levels.

Direct contact of NexoBrid with the eyes should be avoided. If NexoBrid goes into the eyes, wash them with lots of water for at least 15 minutes.

To prevent wound-healing problems, the treated burn wound will be covered as soon as possible by temporary or permanent skin substitutes or dressings.

NexoBrid should not be used in chemical burn wounds, electrical burns, foot burns in diabetic patients and patients with occlusive vascular disease, in contaminated wounds and wounds where NexoBrid could come in contact with foreign materials (for example, implants, pacemakers, and shunts) or large blood vessels, the eyes or other important body parts.

**Children and adolescents**

NexoBrid is not for use in patients younger than 18 years.

**Other medicines and NexoBrid**

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Your doctor will be cautious and watch for signs of reduced blood coagulation or bleeding when prescribing other medicines that affect blood coagulation, because NexoBrid may reduce blood coagulation.

NexoBrid may:
- increase the effects of certain medicines that are inactivated by a liver enzyme called CYP2C8 and CYP2C9. This is because NexoBrid can be absorbed from the burn wound into the blood stream. Examples of such medicines are:
  - amiodarone (used to treat certain forms of irregular heartbeat),
  - amodiaquine and chloroquine (used to treat malaria and some forms of inflammation),
  - fluvastatin (used to treat high cholesterol),
  - pioglitazone, rosiglitazone, repaglinide, tolbutamide and glipizide (used to treat diabetes),
  - paclitaxel and sorafenib (used to treat cancer),
  - torasemide (used to increase urine flow),
  - ibuprofen (used to treat fever, pain and some forms of inflammation),
  - losartan (used to treat high blood pressure),
  - celecoxib (used to treat some forms of inflammation),
warfarin (used to reduce blood coagulation), and
phenytoin (used to treat epilepsy).

- intensify your reaction to the cancer medicines fluorouracil and vincristine.
- cause an unwanted drop in blood pressure when you are treated with medicines called ACE inhibitors, which are used to treat high blood pressure and other conditions.
- increase drowsiness when used at the same time with medicines that can cause drowsiness. These medicines include, for example, sleep medications, so-called tranquilizers, some pain medications and antidepressants.
- Silver sulfadiazine or povidone-iodine at the wound site may decrease the efficacy of the medicinal product.

If you are not sure whether you are taking any of the medicines mentioned above, ask your doctor before NexoBrid is used.

Pregnancy and breast-feeding
The use of NexoBrid during pregnancy is not recommended.
As a precautionary measure, you should not breast-feed for at least 4 days after NexoBrid application.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, talk to your doctor or pharmacist before this medicine is used.

3. How NexoBrid is used

NexoBrid is for use by specialists in burn clinics only. It will be prepared directly before use and applied by a doctor or another healthcare professional.

2 g NexoBrid powder mixed in 20 g gel is applied 1.5 to 3 millimetres thick to a burn wound area of 1 percent of an adult patient’s body surface.

It should be left for 4 hours, and then be removed. A second and subsequent application is not recommended.

- NexoBrid should not be applied to more than 15% of the total body surface.

Instructions for the preparation of the NexoBrid gel are given at the end of this leaflet in the section intended for medical or healthcare professionals.

Before it is applied to a burn wound, NexoBrid powder is mixed into a gel. It should be used within 15 minutes after mixing.

- NexoBrid will be applied to a wound area that is clean, blister free, and moist.
- Other medicines (such as silver sulfadiazine or povidone-iodine) will be removed from the wound area before NexoBrid is applied.
- Before NexoBrid application, a dressing soaked with an antibacterial solution will be applied for 2 hours.
- You will be given appropriate medicine to prevent and treat pain at least 15 minutes before NexoBrid is applied and before removal.
- After NexoBrid and the dead tissue have been removed from the wound, a dressing soaked with an antibacterial solution will be applied for an additional 2 hours.
- The vial containing powder, gel bottle, and the prepared mixed gel are for single use only.

If too much NexoBrid is used
If too much NexoBrid gel is applied on a burn wound, excess gel may be wiped off.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions to NexoBrid can occur and can cause, for example, breathing difficulties, swelling of the skin, hives, redness of the skin, low blood pressure, fast heart rate and sickness/vomiting/stomach cramp, or a combination of such effects. If you notice any of these symptoms or signs, inform your doctor or caregiver immediately.

**Very common** (may affect more than 1 in 10 people)
- Fever

**Common** (may affect up to 1 in 10 people)
- Pain (even if medicines are used to prevent or lessen pain caused by the removal of burnt tissue)
- Infection of the burn wound
- Complications of the wound including wound opening, wounds drying out and breaking down, failure of skin grafts to heal properly

Non serious allergic reactions such as rash.
- Rapid heartbeat

**Not known** frequency (frequency cannot be estimated from the available data)
- Serious allergic reactions including anaphylaxis

**Reporting of side effects**

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How NexoBrid is stored

Keep this medicine out of the sight and reach of children.

Do not use NexoBrid after the expiry date which is stated on the label of the vial, bottle, and box after “EXP”. The expiry date refers to the last day of that month.

Store and transport refrigerated (2°C-8°C).

NexoBrid must be stored upright to keep the gel at the bottom of the bottle and in the original package to protect from light.

Do not freeze.

NexoBrid should be used within 15 minutes after mixing the powder with the gel.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. **Contents of the pack and other information**

**What Nexobrid contains**
- The active substance (in the powder in the vial) is a concentrate of proteolytic enzymes enriched in bromelain: one vial contains 2 g, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing.
- The other ingredients are:
  - for the powder: ammonium sulphate and acetic acid
  - and for the gel carbomer 980, disodium phosphate anhydrous, sodium hydroxide, and water for injections.

**What NexoBrid looks like and contents of the pack**
NexoBrid product is provided as a powder and gel for gel (powder in a vial (2 g) and gel in a bottle (20 g)), pack size of 1 (a pack contains one vial of powder and one bottle of gel)

The powder is off-white to light tan and the gel is clear and colourless.

**Marketing Authorisation Holder**
MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

**Manufacturer**
Diapharm GmbH & Co. KG
Am Mittelhafen 56
48155 Münster
Germany

**This leaflet was last revised in**

**Other sources of information**
Detailed information on this medicine is available on the European Medicines Agency web site: [http://www.ema.europa.eu](http://www.ema.europa.eu). There are also links to other websites about rare diseases and treatments.

---

The following information is intended for healthcare professionals only:

**Preparation and administration**

From a microbiological point of view and as the enzymatic activity of the product decreases progressively following mixing, the reconstituted product should be used immediately after preparation (within 15 minutes).

NexoBrid should be applied to a clean, keratin-free (blisters removed), and moist wound area.

Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to NexoBrid application.

**Preparation of patient and wound area**
- A total wound area of not more than 15% TBSA can be treated by NexoBrid.
Enzymatic debridement is a painful procedure and requires adequate analgesia and/or anaesthesia. Pain management must be used as commonly practiced for an extensive dressing change; it should be initiated at least 15 minutes prior to NexoBrid application.

The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with NexoBrid and prevent eschar removal by NexoBrid.

Dressing soaked with an antibacterial solution must be applied for 2 hours.

All topically applied antibacterial medicinal products must be removed before applying NexoBrid. Remaining antibacterial medicinal products may reduce the activity of NexoBrid by decreasing its efficacy.

The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser). The paraffin layer must not come into contact with the area to be treated in order to avoid covering the eschar, thus isolating the eschar from direct contact with NexoBrid. To prevent possible irritation of abraded skin by inadvertent contact with NexoBrid and possible bleeding from the wound bed, acute wound areas such as lacerations or escharotomy incisions should be protected by a layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).

Sterile isotonic sodium chloride 9 mg/ml (0.9%) solution must be sprinkled on the burn wound. The wound must be kept moist during the application procedure.

**NexoBrid gel preparation (mixing powder with gel)**

- The NexoBrid powder and gel are sterile. Aseptic technique must be used when mixing NexoBrid powder with the gel. The powder should not be inhaled. Wearing of gloves and protective clothing as well as eye shielding glasses and surgical mask, is required.
- The NexoBrid powder vial must be opened by carefully tearing off the aluminium cap and removing the rubber stopper.
- When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle’s cap. If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
- NexoBrid powder is then transferred into the corresponding gel bottle.
- NexoBrid powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained. This usually requires mixing the NexoBrid powder and the gel for 1 to 2 minutes.
- NexoBrid gel should be prepared at the patient’s bedside.

**NexoBrid application**

- Moisten the area to be treated by sprinkling sterile saline onto the area bordered by the fatty ointment adhesive barrier.
- Within 15 minutes of mixing, NexoBrid must be applied topically to the burn wound, at a thickness of 1.5 to 3 millimetres.
- The wound must then be covered with a sterile occlusive film dressing that adheres to the sterile adhesive barrier material applied as per the instruction above (see Preparation of patient and wound area). The NexoBrid gel should fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing. Gentle pressing of the occlusive dressing at the area of contact with the adhesive barrier will ensure adherence between the occlusive film and the barrier and achieve complete containment of NexoBrid on the treatment area.
- The dressed wound must be covered with a loose, thick fluffy dressing, held in place with a bandage.
- The dressing must remain in place for 4 hours.

**Removal of NexoBrid**

- Removal of NexoBrid is a painful procedure and requires adequate analgesia and/or anaesthesia. Appropriate preventive analgesia medicinal products must be administered at least 15 minutes prior to NexoBrid application.
- After 4 hours of NexoBrid treatment, the occlusive dressing must be removed using aseptic techniques.
• The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
• The dissolved eschar must be removed from the wound by wiping it away with a sterile blunt-edged instrument.
• The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution. The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue. Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
• A dressing soaked with an antibacterial solution must be applied for an additional 2 hours.

Wound care after debridement

• The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.
• Before a permanent skin cover or temporary skin substitute is applied to a freshly enzymatically debrided area, a soaking wet-to-dry dressing should be applied.
• Before application of the grafts and primary dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or scraping to allow dressing adherence.
• Wounds with areas of full thickness and deep burn should be autografted as soon as possible after NexoBrid debridement. Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement.

Recommendations for safe handling

Each NexoBrid vial, gel, or reconstituted gel should be used for a single patient only.

There are reports of occupational exposure to bromelain leading to sensitisation. Sensitisation may have occurred due to inhalation of bromelain powder. Allergic reactions to bromelain include anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angioedema, urticaria, and mucosal and gastrointestinal reactions. When mixing NexoBrid powder with the gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and surgical mask, is required. The powder should not be inhaled.

Avoid accidental eye exposure. In case of eye exposure, irrigate exposed eyes with copious amounts of water for at least 15 minutes. In case of skin exposure, rinse NexoBrid off with water.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.
Package leaflet: Information for the user

NexoBrid 5 g powder and gel for gel
concentrate of proteolytic enzymes enriched in bromelain

⚠️ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What NexoBrid is and what it is used for
2. What you need to know before NexoBrid is used
3. How NexoBrid is used
4. Possible side effects
5. How NexoBrid is stored
6. Contents of the pack and other information

1. What NexoBrid is and what it is used for

What NexoBrid is
NexoBrid contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is produced from an extract from the stem of the pineapple plant.

What NexoBrid is used for
NexoBrid is used in adult patients to remove burnt tissue from deep or partially deep burn wounds of the skin.
Using NexoBrid may reduce the need for, or the extent of, surgical removal of burnt tissue and/or skin transplantation.

2. What you need to know before NexoBrid is used

NexoBrid must not be used:
- if you are allergic to bromelain
- if you are allergic to pineapples
- if you are allergic to papain
- if you are allergic to any of the other ingredients of the powder or gel (listed in section 6).

Warnings and precautions
Talk to your doctor or nurse before NexoBrid is used if:
- you have a heart disease;
- you have diabetes;
- you have an active peptic ulcer in the stomach,
- you have a vascular disease (with vascular occlusion);
- you have implants or a pacemaker or a vascular shunt;
- you have problems with bleeding or if you take blood-thinners;
- your wound(s) came into contact with chemicals or other hazardous substances;
- you have a lung disease;
- your lung has been, or may have been damaged by inhalation of smoke;
- you are allergic to latex, bee stings, or olive tree pollen. If so, you may also experience allergic reactions to NexoBrid.

Allergic reactions can cause, for example, breathing difficulties, swelling of the skin, hives, other skin reactions, redness of the skin, low blood pressure, fast heart rate and abdominal discomfort, or a combination of such effects. If you notice any of these signs or symptoms, inform your doctor or caregiver immediately.

Allergic reactions can be severe and require medical treatment.

In case of skin contact, rinse NexoBrid off with water. This is to make it less likely that you develop an allergic reaction to NexoBrid.

The use of NexoBrid to remove burnt tissue may lead to fever, to wound inflammation or wound infection, and possibly to general infection. You may be checked regularly for these conditions. You may receive medicines to prevent or treat infections.

NexoBrid may reduce the ability of your blood to form clots, which increases the risk of bleeding. NexoBrid should be used with caution if you are treated with medicines that reduce your blood’s ability to form clots (so-called blood-thinners) or if you have a general tendency to bleed, a stomach ulcer, blood poisoning, or another condition that could cause you to bleed. After treatment with NexoBrid your doctor may check your blood coagulation levels.

Direct contact of NexoBrid with the eyes should be avoided. If NexoBrid goes into the eyes, wash them with lots of water for at least 15 minutes.

To prevent wound-healing problems, the treated burn wound will be covered as soon as possible by temporary or permanent skin substitutes or dressings.

NexoBrid should not be used in chemical burn wounds, electrical burns, foot burns in diabetic patients and patients with occlusive vascular disease, in contaminated wounds and wounds where NexoBrid could come in contact with foreign materials (for example, implants, pacemakers, and shunts) or large blood vessels, the eyes or other important body parts.

**Children and adolescents**

NexoBrid is not for use in patients younger than 18 years.

**Other medicines and NexoBrid**

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Your doctor will be cautious and watch for signs of reduced blood coagulation or bleeding when prescribing other medicines that affect blood coagulation, because NexoBrid may reduce blood coagulation.

**Other medicines and NexoBrid**

Tell your doctor if you are taking, have recently taken or might take any other medicines.

Your doctor will be cautious and watch for signs of reduced blood coagulation or bleeding when prescribing other medicines that affect blood coagulation, because NexoBrid may reduce blood coagulation.

NexoBrid may:

- increase the effects of certain medicines that are inactivated by a liver enzyme called CYP2C8 and CYP2C9. This is because NexoBrid can be absorbed from the burn wound into the blood stream. Examples of such medicines are:
  - amiodarone (used to treat certain forms of irregular heartbeat),
- amodiaquine and chloroquine (used to treat malaria and some forms of inflammation),
- fluvastatin (used to treat high cholesterol),
- pioglitazone, rosiglitazone, repaglinide, tolbutamide and glipizide (used to treat diabetes),
- paclitaxel and sorafenib (used to treat cancer),
- torasemide (used to increase urine flow),
- ibuprofen (used to treat fever, pain and some forms of inflammation),
- losartan (used to treat high blood pressure),
- celecoxib (used to treat some forms of inflammation),
- warfarin (used to reduce blood coagulation), and
- phenytoin (used to treat epilepsy).

- intensify your reaction to the cancer medicines fluorouracil and vincristine.
- cause an unwanted drop in blood pressure when you are treated with medicines called ACE inhibitors, which are used to treat high blood pressure and other conditions.
- increase drowsiness when used at the same time with medicines that can cause drowsiness. These medicines include, for example, sleep medications, so-called tranquilizers, some pain medications and antidepressants. Silver sulfadiazine or povidone-iodine at the wound site may decrease the efficacy of the medicinal product.

If you are not sure whether you are taking any of the medicines mentioned above, ask your doctor before NexoBrid is used.

**Pregnancy and breast-feeding**
The use of NexoBrid during pregnancy is not recommended. As a precautionary measure, you should not breast-feed for at least 4 days after NexoBrid application. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, talk to your doctor or pharmacist before this medicine is used.

**3. How NexoBrid is used**

NexoBrid is for use by specialists in burn clinics only. It will be prepared directly before use and applied by a doctor or another healthcare professional.

5 g NexoBrid powder mixed in 50 g gel is applied 1.5 to 3 millimetres thick to a burn wound area of 2.5 percent of an adult patient’s body surface.

It should be left for 4 hours, and then be removed. A second and subsequent application is not recommended.

- NexoBrid should not be applied to more than 15% of the total body surface.

Instructions for the preparation of the NexoBrid gel are given at the end of this leaflet in the section intended for medical or healthcare professionals.

Before it is applied to a burn wound, NexoBrid powder is mixed into a gel. It should be used within 15 minutes after mixing.

- NexoBrid will be applied to a wound area that is clean, blister free, and moist.
- Other medicines (such as silver sulfadiazine or povidone-iodine) will be removed from the wound area before NexoBrid is applied.
- Before NexoBrid application, a dressing soaked with an antibacterial solution will be applied for 2 hours.
- You will be given appropriate medicine to prevent and treat pain at least 15 minutes before NexoBrid is applied and before removal.

62
• After NexoBrid and the dead tissue have been removed from the wound, a dressing soaked with an antibacterial solution will be applied for an additional 2 hours.

• The vial containing the powder, gel bottle, and the prepared gel are for single use only.

**If too much NexoBrid is used**
If too much NexoBrid gel is applied on a burn wound, excess gel may be wiped off.

If you have any further questions on the use of this medicine, ask your doctor.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions to NexoBrid can occur and can cause, for example, breathing difficulties, swelling of the skin, hives, redness of the skin, low blood pressure, fast heart rate and sickness/vomiting/stomach cramp, or a combination of such effects. If you notice any of these symptoms or signs, inform your doctor or caregiver immediately.

**Very common** (may affect more than 1 in 10 people)
- Fever

**Common** (may affect up to 1 in 10 people)
- Pain (even if medicines are used to prevent or lessen pain caused by the removal of burnt tissue)
- Infection of the burn wound
- Complications of the wound including wound opening, wounds drying out and breaking down, failure of skin grafts to heal properly
- Non serious allergic reactions such as rash.
- Rapid heartbeat

**Not known** (frequency cannot be estimated from the available data)
- Serious allergic reactions including anaphylaxis

**Reporting of side effects**

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How NexoBrid is stored**

Keep this medicine out of the sight and reach of children.

Do not use NexoBrid after the expiry date which is stated on the label of the vial, bottle, and box after “EXP”. The expiry date refers to the last day of that month.

Store and transport refrigerated (2°C-8°C).

NexoBrid must be stored upright to keep the gel at the bottom of the bottle and in the original package to protect from light.
Do not freeze.

NexoBrid should be used within 15 minutes after mixing the powder with the gel.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Nexobrid contains
- The active substance (in the powder in the vial) is a concentrate of proteolytic enzymes enriched in bromelain: one vial contains 2 g, corresponding to 0.09 g/g concentrate of proteolytic enzymes enriched in bromelain after mixing.
- The other ingredients are:
  o for the powder: ammonium sulphate and acetic acid
  o and for the gel: carbomer 980, disodium phosphate anhydrous, sodium hydroxide, and water for injections.

What NexoBrid looks like and contents of the pack
NexoBrid is provided as a powder and gel for gel (powder in a vial (5 g) and gel in a bottle (50 g)), pack size of 1 (a pack contains one vial of powder and one bottle of gel)

The powder is off-white to light tan and the gel is clear and colourless.

Marketing Authorisation Holder
MediWound Germany GmbH
Hans-Sachs-Strasse 100
65428 Rüsselsheim
Germany
e-mail: info@mediwound.com

Manufacturer
Diapharm GmbH & Co. KG
Am Mittelhafen 56
48155 Münster
Germany

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.

The following information is intended for healthcare professionals only:

Preparation and administration

From a microbiological point of view and as the enzymatic activity of the product decreases progressively following mixing, the reconstituted product should be used immediately after preparation (within 15 minutes).

NexoBrid should be applied to a clean, keratin-free (blisters removed), and moist wound area.

Topically applied medicinal products (such as silver sulfadiazine or povidone-iodine) at the wound site must be removed and the wound must be cleansed prior to NexoBrid application.
Preparation of patient and wound area

- A total wound area of not more than 15% TBSA can be treated by NexoBrid.
- Enzymatic debridement is a painful procedure and requires adequate analgesia and/or anaesthesia. Pain management must be used as commonly practiced for an extensive dressing change; it should be initiated at least 15 minutes prior to NexoBrid application.
- The wound must be cleaned thoroughly and the superficial keratin layer or blisters removed from the wound area, as the keratin will isolate the eschar from direct contact with NexoBrid and prevent eschar removal by NexoBrid.
- Dressing soaked with an antibacterial solution must be applied for 2 hours.
- All topically applied antibacterial medicinal products must be removed before applying NexoBrid. Remaining antibacterial medicinal products may reduce the activity of NexoBrid by decreasing its efficacy.
- The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser). The paraffin layer must not come into contact with the area to be treated in order to avoid covering the eschar, thus isolating the eschar from direct contact with NexoBrid.
- To prevent possible irritation of abraded skin by inadvertent contact with NexoBrid and possible bleeding from the wound bed, acute wound areas such as lacerations or escharotomy incisions should be protected by a layer of a sterile fatty ointment or fatty dressing (e.g. petrolatum gauze).
- Sterile isotonic sodium chloride 9 mg/ml (0.9%) solution must be sprinkled on the burn wound. The wound must be kept moist during the application procedure.

NexoBrid gel preparation (mixing powder with gel)

- The NexoBrid powder and gel are sterile. Aseptic technique must be used when mixing NexoBrid powder with the gel. The powder should not be inhaled. Wearing of gloves and protective clothing as well as eye shielding glasses and surgical mask, is required.
- The NexoBrid powder vial must be opened by carefully tearing off the aluminium cap and removing the rubber stopper.
- When opening the gel bottle, it must be confirmed that the tamper-evident ring is separating from the bottle’s cap. If the tamper-evident ring was already separated from the cap before opening, the gel bottle must be discarded and another, new gel bottle used.
- NexoBrid powder is then transferred into the corresponding gel bottle.
- NexoBrid powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained. This usually requires mixing the NexoBrid powder and the gel for 1 to 2 minutes.
- NexoBrid gel should be prepared at the patient’s bedside.

NexoBrid application

- Moisten the area to be treated by sprinkling sterile saline onto the area bordered by the fatty ointment adhesive barrier.
- Within 15 minutes of mixing, NexoBrid must be applied topically to the burn wound, at a thickness of 1.5 to 3 millimetres.
- The wound must then be covered with a sterile occlusive film dressing that adheres to the sterile adhesive barrier material applied as per the instruction above (see Preparation of patient and wound area). The NexoBrid gel should fill the entire occlusive dressing, and special care should be taken not to leave air under this occlusive dressing. Gentle pressing of the occlusive dressing at the area of contact with the adhesive barrier will ensure adherence between the occlusive film and the barrier and achieve complete containment of NexoBrid on the treatment area.
- The dressed wound must be covered with a loose, thick fluffy dressing, held in place with a bandage.
- The dressing must remain in place for 4 hours.

Removal of NexoBrid

- Removal of NexoBrid is a painful procedure and requires adequate analgesia and/or anaesthesia. Appropriate preventive analgesia medicinal products must be administered at least 15 minutes prior to NexoBrid application.
• After 4 hours of NexoBrid treatment, the occlusive dressing must be removed using aseptic techniques.
• The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
• The dissolved eschar must be removed from the wound by wiping it away with a sterile blunt-edged instrument.
• The wound must be wiped thoroughly first with a large sterile dry gauze or napkin, followed by a sterile gauze or napkin that has been soaked with sterile isotonic sodium chloride 9 mg/ml (0.9%) solution. The treated area must be rubbed until the appearance of a pinkish surface with bleeding points or a whitish tissue. Rubbing will not remove adhering undissolved eschar in areas where the eschar still remains.
• A dressing soaked with an antibacterial solution must be applied for an additional 2 hours.

Wound care after debridement
• The debrided area must be covered immediately by temporary or permanent skin substitutes or dressings to prevent desiccation and/or formation of pseudoeschar and/or infection.
• Before a permanent skin cover or temporary skin substitute is applied to a freshly enzymatically debrided area, a soaking wet-to-dry dressing should be applied.
• Before application of the grafts and primary dressing, the debrided bed must be cleaned and refreshed by, e.g., brushing or scraping to allow dressing adherence.
• Wounds with areas of full thickness and deep burn should be autografted as soon as possible after NexoBrid debridement. Careful consideration should also be given to placing permanent skin covers (e.g. autografts) on deep partial thickness wounds soon after NexoBrid debridement.

Recommendations for safe handling

Each NexoBrid vial, gel, or reconstituted gel should be used for a single patient only.

There are reports of occupational exposure to bromelain leading to sensitisation. Sensitisation may have occurred due to inhalation of bromelain powder. Allergic reactions to bromelain include anaphylactic reactions and other immediate-type reactions with manifestations such as bronchospasm, angiooedema, urticaria, and mucosal and gastrointestinal reactions. When mixing NexoBrid powder with the gel, appropriate handling, including wearing of gloves and protective clothing as well as eye shielding glasses and surgical mask, is required. The powder should not be inhaled.

Avoid accidental eye exposure. In case of eye exposure, irrigate exposed eyes with copious amounts of water for at least 15 minutes. In case of skin exposure, rinse NexoBrid off with water.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.